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ABSTRACT 
 
Magnetic fluid hyperthermia is a potential therapy for achieving interstitial hyperthermia 
and is currently under clinical trials. This approach is based on the instillation of magnetic 
nanoparticles at the tumour site, which dissipate heat when exposed to an alternating 
magnetic field. This procedure leads to a local increase of temperature and induction of 
tumour death or regression. Nanoparticles of metallic iron are potential heating agents for 
this therapy, but rely on the presence of a protecting coat that avoids reactions with their 
environment. In this work, iron nanospheres and iron nanowires with a graphite coat are 
explored for this purpose. From these two nanostructures, the nanospheres are shown to 
have a greater potential in terms of heat dissipation. The graphite shell is further 
investigated as an interface for conjugation with other molecules of relevance such as 
drugs and fluorescent probes. The effect of acidic treatments on the magnetic and surface 
properties of the nanospheres is systematically studied and a suitable method to generate 
carboxylic functionalities on the nanoparticle surface alongside with a good preservation 
of the magnetic properties is developed. These carboxylic groups are shown to work as a 
bridge for conjugation with a model molecule, methylamine, as well as with a fluorescent 
dye, allowing the detection of the nanoparticles in cells by means of optical methods. The 
carboxylic functionalities are further explored for the conjugation with the anti-cancer 
drug cisplatin, where the amount of drug loaded per particle is found to be dependent on 
the density of free carboxylic groups. The release of the drug in physiological salt 
solutions is time and temperature dependent, making them particularly interesting for 
multi-modal anti-cancer therapies, where concomitant hyperthermia and chemotherapy 
could be achieved. Their potential for such therapies is shown in vitro by inducing 
hyperthermia in cell suspensions containing these nanoparticles. These results are finally 
translated to a three-dimensional cell culture model where the in vitro growth of tumour 
spheroids is inhibited. The developed nanostructures have a great potential for therapeutic 
approaches based on the synergistic effects of hyperthermia and chemotherapy. 
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 INTRODUCTION 
 
 
1.1 The Biological and Clinical Foundations of Hyperthermia 
 
1.1.1 The Basis of Tumour Heat Sensitivity 
 
The idea of using heat to kill malignancies can be traced back to ancient history. The 
Edwin Smith Surgical Papyrus, one of the world’s oldest medical literatures dating back to 
3000 B.C. reports the use of heat for treating breast cancer [1]. Such treatments were also 
described in subsequent reports by Greek and Roman physicians and were as well a very 
prominent treatment for cancer and other disorders from antiquity through to the 
nineteenth century [2]. 
In older times, however, the use of heat was limited to externally accessible regions of 
the body and applied for cautery only, a condition in which tissue is damaged due the 
extremely high temperatures. It was only in the late eighteen-hundreds that the American 
surgeon J. Byrne recognised that “deeper laying cancer cells are destroyed by less heat 
than will destroy normal tissues”, indicating that cancer cells could have a higher 
sensibility to heat. It was also at this time that studies involving moderate temperatures 
(< 46 oC) began [2]. 
According to Habash et al. [3], all therapeutic treatments based on the transfer of 
thermal energy into or out of the body are classified as thermotherapy. That includes 
thermoablation, hyperthermia and cryotherapy. For cancer therapies, the first two ones 
are of greater interest. In thermoablation, temperatures above 47 oC are applied at the 
tumour site, resulting in acute necrosis, coagulation or carbonisation of the tissue. 
Hyperthermia, on the other hand, involves more moderate temperatures, generally 
between 42 oC and 46 oC [4]. In this temperature range, cancer tissue is more sensitive 
than the normal counterparts and thus, tumour damage can be induced while the 
surrounding healthy tissue is preserved. 
In contrast to other anti-cancer therapies hyperthermia does not appear to have a 
specific target in the cell. Whereas the effect of radiation therapy on DNA and the mode 
1 
 of action of most drugs are relatively well understood, the mechanism of cell death 
induced by hyperthermia has not yet been thoroughly described [5]. 
It is recognised though, that the main event underlying the biological effects of 
hyperthermia is protein damage [6]. For many cells and tissues, the activation energies for 
cell death are in the range of that necessary for protein denaturation (130-170 kcal/mol) 
[7]. Additionally, an increase in the expression of heat shock proteins (HSP) is observed in 
cells upon heating [6], indicating that proteins are loosing their conformation. Streffer [5] 
reviews several studies concerning the extent of cell damage inflicted by protein 
denaturation following hyperthermia. Those studies show alterations in several 
multimolecular structures such as the cytoskeleton, membranes and also of structures in 
the cell nucleus. The existence of a specific target that leads to cell death is nevertheless 
unknown. 
Protein damage and its consequences during hyperthermia are not limited to malignant 
cells. In fact, all cells display a certain level of thermal sensitivity when cultured in vitro. A 
cell killing effect is observed in the range of 41 oC to 46 oC in varying degrees according to 
the tissue of origin [8, 9] and the species of the cell [8, 10]. The thermal sensitivity 
however, is not related to the cell normal/malignant status [5, 8, 11] and it is now believed 
that there is no difference in hyperthermia sensitivity between normal and tumour cells. In 
fact, even cells originating from tumours of the same histological type can show a varied 
sensibility to temperature [12]. Thus, it is difficult to establish how vulnerable different 
cells are to temperature when cultured in vitro.  
On the other hand, evidence from early in vivo studies conducted in the 20s and 30s do 
demonstrate the possibility of delaying or inhibiting tumour growth without damage to 
the surrounding tissues upon application of hyperthermia, suggesting a higher thermal 
sensivity of malignant tissues [2]. The disagreement between in vitro and in vivo studies is 
now understood to result from tumour physiology. 
When compared to normal tissues, tumours have an irregular and abnormal 
microvasculature (Figure 1.1), leading to an increase in resistance to blood flow that 
impairs an efficient blood supply. The limited blood flow leads to hypoxia (low oxygen 
tension), given the low supply of oxygen; low glucose levels, given the limited supply of 
nutrients and low pH values resulting from the lactate production in response to hypoxia 
and the build up of cell metabolic products [13]. 
These conditions lead to a harsher environment in the tumours which is not seen in 
healthy tissues or in in vitro culture where oxygen, nutrients and pH are evenly balanced. 
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These microenvironmental changes are the factors responsible for the increased 
sensitivity of tumour cells to higher temperatures [14]. In fact, when such conditions are 
applied to cells cultured in vitro, they become more sensitive to heat. Research has shown 
an enhanced response to hyperthermia in vitro when cells are cultured under acidic, 
hypoxic and/or nutrient-depleted conditions [15, 16].  
 
 
 
Figure 1.1. Schematic representation of the vascular system. (A) corresponds to normal 
tissue and (B) to a solid tumour. Abnormalities that lead to a chaotic structure are indicated. 
Reproduced from reference [13]. 
 
When hyperthermia is applied, metabolic rates also become relevant. At higher 
temperatures, cell metabolic rate is increased and energy reservoirs are utilised and 
depleted [5]. Such alterations can lead to further changes in pH and nutrient availability, 
escalating thermal sensitivity. 
Hence, several factors can be involved in the higher susceptibility of tumour cells to 
damage by heat. Vaupel and Kelleher [17] suggest that intracellular pH and bioenergetic 
status may be the decisive factors that modulate the thermosensitivity of cancer cells. This 
is in connection with the fact that low intracellular pH also reduces the stability of 
proteins and that energy is steadily needed in order to maintain the micromileu and with it 
the conformation of cellular structures in general [5]. 
Apart from the local cell death, hyperthermia also affects immune regulation. Heat 
shock proteins are normally found in the intracellular space only and if released in the 
extracellular milieu they trigger a response from the immune system [18]. In 
thermotherapy, such a situation is realised when upon heating, necrotic cells release HSP 
in the extracellular space triggering an immunogenic response. Apart from a direct release 
during necrosis, there have also been indications that HSP can be expressed on the 
surface of cancer cells after heat shock, what could also trigger an immune response [19]. 
 The release of HSP in the extracellular space has also been suggested to function as an 
autologous vaccination against the malignant cells [20]. During the heat shock, HSP 
expression is increased to help chaperone the denatured proteins. If the denaturation 
cannot be reversed, the misfolded proteins are processed by proteasomes and degraded 
into smaller peptides. It has been found that HSP also bind to those small peptides in 
order to stabilise them [18, 20]. That means that in the case of malignant cells the 
degradation of oncoproteins results in complexes that contain particular mutations and 
translocations which are not found in healthy cells. If such complexes are released during 
necrosis, they can be presented to antigen presenting cells, promoting immune response. 
This process is very effective since macrophages and dendritic cells have HSP receptors 
[18, 21].   
 
1.1.2 Hyperthermia as an Enhancer of Radiotherapy and 
Chemotherapy 
 
Although hyperthermia does enhance tumour regression, its application as a standalone 
therapy is not currently effective enough to replace any of the established therapy 
modalities. It is, however, certainly suitable to enhance the effects of radiotherapy and 
chemotherapy [22].  
Radiation therapy is based on DNA damage inflicted by ionizing radiation. Normally, 
cells have a battery of repair mechanisms to maintain genomic stability. Some lesions, 
however, are particularly toxic to cells since they are more difficult to repair. Those are the 
DNA double strand breaks (dsb) and some classes of clustered lesions. One way to 
increase the strength of the therapy would be to inhibit the repair mechanism of DNA 
damage and significant effort is currently in progress on the development of drugs that 
could target such mechanisms [23]. Hyperthermia, on the other hand, inhibits those 
mechanisms by itself. The denaturation, inactivation and aggregation of cellular proteins 
leads to the loss of activity of rate-limiting DNA repair enzymes or to the alteration in 
chromatin structure [24], conditions which inhibit DNA repair. The amount of pre-
clinical data showing these effects resulted in the translation of the combined therapy to 
clinical trials. A meta-analysis of several trials conducted up to 2007 has shown significant 
improvements in the treatment of tumours in the chest wall, cervix, rectum, bladder, 
melanoma, head and neck when hyperthermia is combined with radiotherapy [25].  
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Heat has also been found to modify the cytotoxicity of many chemotherapeutic agents 
at different levels. Alkylating agents, platinum compounds and nitrosoureas, for example, 
have a linear enhancement in their cytotoxic effect when temperatures are raised from 
37 oC to over 40 oC. Doxorubicin and bleomycin, in contrast, display a threshold 
temperature for the interaction which lies at about 42.5 oC. Other drugs such as 
antimetabolites, vinca-alcaloids and taxanes display an independent action [26]. The 
mechanisms for drug potentialisation do vary according to the target of the drug. Some 
effects of hyperthermia are however common to most of them. Those include a higher 
uptake of the drug, increased oxygen radical production and increased DNA damage and 
inhibition of repair, in the cases of drugs which have DNA damage as a target [27]. 
Another indirect benefit of hyperthermia for drug treatment is an increased delivery of 
drug to the tumour. Blood flow and vascular permeability are increased by heat [26] 
partially overcoming the limited drug distribution that is observed as a consequence of the 
poor blood supply in tumours. 
 
1.1.3 Heat Dosage and Thermotolerance 
 
The therapeutic effect of hyperthermia alone or in combination with radiotherapy and 
chemotherapy depends on the temperature and exposure time involved. In clinical 
practice, however, estimating the heat dosage might prove difficult. At first, because the 
heating cycle until the predetermined exposure temperature is achieved can significantly 
account to the hyperthermic effect. Second, because the target temperature or condition 
might not always be realised. Patient discomfort, tumour location, blood flow and 
equipment limitations might limit the temperatures achievable. The lower temperatures to 
which the patient would be exposed would however still have an effect [28]. More 
complications arise when crossing the data of different patients whose treatments are 
performed at different temperatures, making the comparison of the therapeutic outcome 
difficult. 
In order to standardise data referent to different treatment cycles, Saparetto and Dewey 
[28] suggested the normalisation of hyperthermia cycles to the number of equivalent 
minutes at 43 oC. They observed that an exponential relationship exists between time and 
temperature and that in most systems “one degree increase in temperature results a two-
fold decrease in time for the same effect above 43 oC and a three to four fold decrease in 
 time for an iso-effect below 43 oC.” leading to the formulation of the following 
relationship: 
 
)43()()43( To RtCCEM −∑ Δ=  
 
Where CEM(43 oC) corresponds to the cumulative equivalent minutes at 43 oC, t to the 
treatment period, R to a constant and T to the treatment temperature. The constant R is 
taken as 0.5 for T  > 43 oC and 0.25 for T  < 43 oC. This equation allows the comparison 
of different treatments and to the realisation that a treatment of 30 minutes at 44 oC, for 
example, should have the same thermal effect as a treatment for 240 minutes at 42 oC (i.e. 
both have a CEM(43 oC) of 60 minutes). 
The clinical application of hyperthermia, in general, involves multiple exposures of the 
tumours to elevated temperatures [29]. When planning a treatment regime, 
thermotolerance is an effect that must be taken into consideration. As it was previously 
discussed, protein denaturation by hyperthermia triggers the expression of HSP. The 
mechanism for heat shock response has an autoregulatory loop: HSP normally keep the 
responsible transcription factor (HSP-1) inactive but upon heating, HSP bind with higher 
affinity to unfolded proteins, triggering the release of HSP-1 from HSP and initiating the 
HSP transcription [6]. Once HSP levels are sufficiently high, protein aggregation can be 
reversed. Figure 1.2 shows some of the events induced by hyperthermia in respect to 
protein damage and HSP expression. It is observed that HSP levels stay high for a long 
period after the hyperthermia session. This effect leads to the phenomena of 
thermotolerance, in which a subsequent heat treatment performed in this time period is 
not as efficient as the first one, a consequence of the HSP being already at higher levels 
thus, facilitating the repair and removal of the heat induced damage [29]. The time for 
HSP levels to decay is proportional to the strength of the heat shock and research in vitro 
has shown that it can take up to several days [11, 28]. For this reason a minimum of 48 h 
between hyperthermia fractions has been suggested in most clinical trials in order to avoid 
retreatment during thermotolerance [11]. 
The timing of these molecular events also plays a role when hyperthermia is combined 
with other treatments. In order to maximise the effects of DNA damage with 
radiotherapy and drugs that rely on this mechanism, these modalities should be applied 
concomitantly with the heat shock. In the case of radiotherapy, several studies have 
Equation 1.1 
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shown that the synergy looses its potency if radiation is performed after the heat 
treatment (Figure 1.2, TER values), since HSP reduce protein damage at the nucleus [6].  
 
  
 
Figure 1.2. Schematic representation of the kinetics of HSP up-regulation after 
heating, development of thermotolerance (TT), expression of cell death after 1st 
treatment, magnitude of thermal enhancement ratio (TER) and the amount of protein 
aggregation after heating. HS corresponds to the heat shock (hyperthermia). TER is 
defined as the ratio of doses required to kill a fixed percentage of cells with radiation alone or 
with heat plus radiation. Data points do not represent measured data and are for illustrative 
purposes only. Adapted from reference [6]. 
 
1.1.4 An Overview of Heating Methods in Clinical Practice 
 
In clinical practice, three methods exist for the application of hyperthermia: local, 
regional and whole body hyperthermia (WBH) [30, 31]; all of them relying on external 
means to transfer energy to tissues.  
Local hyperthermia aims at heating the tumour volume only, with heat being applied to 
a small area with external, interstitial or endocavitary devices. External apparatuses usually 
consist of a microwave or ultrasound applicator (Figure 1.3a) that can be applied to 
cutaneous or subcutaneous superficial tumours (melanoma, breast cancer, head and neck 
cancer [30]). Interstitial appliances, on the other hand, can be applied to tumours which 
seat deeper within the body. Those are based on antennas or applicators that can be 
inserted within the tumour and are suitable for those which are feasible for implantation 
such as the head, neck and the prostate [31]. Under anaesthesia, probes or small needles 
 are inserted into the tumour to produce a localised deposition of heat [30] through the use 
of microwave antennas, radiofrequency electrodes, ultrasound transducers, heat sources 
(hot water) and laser fibres [31] (Figure 1.3b). Endocavitary devices are based on the same 
physical principles as interstitial antennas [31] and are used to treat tumours within or near 
body cavities such as the oesophagus, rectum, vagina, cervix, uterus, prostate, bladder, 
trachea and bronchus [30]. 
 
c. Regional Heating Device
(Focused Radiofrequency)
BSD Medical BSD 2000/3D
a. Local Heating Device
(External, Microwave based)
BSD Medical BSD 500
d. Whole Body Heating Device
(Infrared Radiation)
Heckel – HT300
b. Local Heating Device
(Interstitial, Radiofrequency based)
Angiodynamics Starbust MRI  
 
Figure 1.3. Hyperthermia devices applied in clinical practice. Images obtained from 
the respective manufacturers. 
 
In the case of deep-seated tumours, such as the pelvis and abdomen, heating can be 
accomplished by arrays of antennas which are positioned around the target region (Figure 
1.3c) in which the energy is focused at the tumour. Energy is however also deposited in 
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the adjacent healthy tissues, leading to increased temperatures in the vicinity of the 
tumour. This modality is termed regional hyperthermia and given its higher complexity, 
requires more sophisticated planning, thermometry and quality assurance [30]. A second 
form of regional hyperthermia is termed regional perfusion, where some of the patients 
blood is removed, heated and then pumped (perfused) back into the limb or organ, often 
in combination with drugs [30]. This method is however expensive, invasive and might be 
associated with major adverse effects and thus cannot be recommended as a standard 
treatment as yet [31].  
For situations involving metastatic spread, the use of WBH is under study. In such 
systems, the whole body of the patient is heated to temperatures of 41.8-42 oC via the 
application of radiant systems based on the emission of infrared waves (Figure 1.3d). 
These extreme conditions require deep analgesia and sedation or general anaesthesia and 
intensive medical care, still with side effects [31]. 
 
1.2 Magnetically Mediated Hyperthermia 
 
1.2.1 Thermoseeds and Nanoparticles for Magnetic Hyperthermia 
 
Although means for inducing hyperthermia are available for the clinic, the local, 
uniform heating of tumours remains difficult. This is mainly true for deep-seated tumours 
where interstitial techniques are rather invasive and the options of regional heating and 
WBH result in increased temperatures in the adjacent tissues, besides being limited to 
moderate temperatures. In fact, it is recognised that the homogenous heating of the 
treated tumour tissue is one of the greatest challenges in hyperthermia [31-33]. An 
interstitial heating method which could partially address those limitations was reported by 
Gilchrist and co-workers in 1957 [34]. Their method was based on the use of magnetic 
nanoparticles that could be injected into the tumour and excited with an alternating 
magnetic field, leading to the dissipation of heat at the malignant tissue (Figure 1.4). This 
pioneering work led to significant research on the use of magnetic implants that could be 
used as a source of heat. One advantage of the method is that local heating is achieved 
without the need of a physical connection of the heating element with the power supply, 
as it is the case of other interstitial heating devices [4, 35]. Furthermore, because the 
 magnetic fields are harmless to the patient, no invasive procedures are necessary for the 
hyperthermia sessions apart from the initial implantation of the magnetic medium [35]. 
Even though the early work of Gilchrist et al. was based on magnetic nanoparticles, the 
first clinical studies using magnetic materials for inducing hyperthermia employed 
thermoseeds [36, 37], a technique that was first described 9 years later [38]. In this 
method, needle sized rods made of a ferromagnetic material are implanted at the tumour 
site as the source of heat. The first thermoseeds were made of stainless steel but modern 
ones are based on advanced materials such as cobalt-palladium (CoPd) alloys, which 
besides having a good biocompatibility [39] allow the realisation of smart temperature 
switches to prevent overheating. This is accomplished given a physical property called 
“curie temperature”, the temperature at which the material does not behave as a 
ferromagnet anymore and thus, it stops heating even if the magnetic field is still applied. 
For CoPd alloys, this property can be adjusted to hyperthermia relevant temperatures 
(45-60 oC) according to the stoichiometry of the alloy [40] thus allowing the thermoseeds 
to stop heating once the therapeutic temperatures are achieved. 
 
Tumour
Implantation of 
Magnetic Seeds/Fluid
Increased T
Alternating
Magnetic Field
Tumour
Supression/Regression
 
 
Figure 1.4. Schematic representation of a therapeutic strategy employing magnetic 
probes to induce hyperthermia. Magnetic probes are implanted in the tumour of the 
patient. The patient is exposed to an alternating magnetic field which interacts with the probes 
leading to the release of heat and local hyperthermia. Following one or more hyperthermia 
sessions, tumour growth is suppressed. 
 
The original idea of using magnetic nanoparticles, however, is of greater interest for 
hyperthermia. This is mainly related to the temperature distribution within the tumour. 
When using thermoseeds, several rods (up to 80) [37] are implanted about 1 cm apart in 
order to heat the whole malignant tissue. The rods are arranged in an array which must be 
aligned in relation to the magnetic field being applied in order to maximise heating. The 
heating between the rods relies on conduction and thus, is not very efficient and requires 
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them to be heated to higher temperatures in order to reach an average of about 43 oC in 
the tumour volume. Liquid suspensions of magnetic nanoparticles, on the other hand, are 
more easily implanted and tumour infiltration is better, leading to a more homogeneous 
temperature distribution [41]. Another advantage of this method is that an array 
arrangement is not necessary and the magnetic field can be applied in any direction thus, 
facilitating the treatment. Considerable research has been done in the direction of 
applying such system for interstitial hyperthermia. Currently, clinical trials are being 
conducted using magnetic nanoparticles made of iron oxides. Colloidal suspensions of 
such nanoparticles, often termed “magnetic fluids” are applied for the treatments and the 
term “magnetic fluid hyperthermia” (MFH) has been coined for the therapy. Positive 
results have been recently obtained in clinical trials involving gliobastoma multiforme [42] 
and prostate cancer [43] and its use for other malignancies is currently under study.  
 
1.2.2 Physical Principles of Magnetic Nanoparticle Heating 
 
In order to identify which parameters and conditions are needed for obtaining heat 
using magnetic materials, an understanding of their magnetic properties is necessary. In 
ferromagnetic materials, the magnetic moments of atoms (spins) interact with each other, 
leading to an ordering in parallel directions. In bulk ferromagnetic materials, magnetic 
moments having the same orientation are organised in regions called “magnetic domains”, 
which are separated by “domain walls”. Each domain has a permanent magnetisation in a 
certain direction. The orientation of the domains is however random in the bulk material 
resulting in a zero net magnetisation (Figure 1.5a); a configuration which is more 
energetically favourable. When exposed to a sufficiently large magnetic field, the domains 
with magnetisation direction along the magnetic field axis grow and the others shrink in a 
phenomenon called “domain wall displacement” [44] (Figure 1.5b) until all spins are 
aligned in the direction of the magnetic field (Figure 1.5c). At this configuration, the 
material reaches its magnetisation saturation (Ms) as observed at the plateau in Figure 
1.5d. When the magnetic field is removed, its magnetisation does not relax back to the 
initial situation. Some energy is stored resulting in a net magnetisation which corresponds 
to the remanent magnetisation (Mr). In order to reduce the magnetisation back to zero, a 
magnetic field of a certain magnitude must be applied in the opposite direction which is 
termed coercivity or coercive field (Hc). The same behaviour is observed when a magnetic 
 field is reapplied in the opposite direction as observed in Figure 1.5d. This lack of 
retraceability of the magnetisation curve is called hysteresis, since the material retains a 
“memory” of its magnetisation.  
 
A
B
C
(A)
(B)
(C)
Magnetisation (M)
Magnetic Field (H)
Saturation
Magnetisation (Ms)
Saturation
Magnetisation (-Ms)
Coercive
Field (Hc)
Coercive
Field (-Hc)
Remanent 
Magnetisation (Mr)
(D)  
 
Figure 1.5. Hypothetic domain configuration and hysteresis loop for a ferromagnetic 
material. The domain configuration illustrated in A-C corresponds to equivalent letters 
indicated in D. Arrows indicate magnetisation when a ferromagnetic material is first exposed 
to a magnetic field. 
 
When a multidomain particle such as the one represented in Figure 1.5 is exposed to an 
oscillating magnetic field, it will continuously magnetise and demagnetise according to its 
hysteresis loop. Given the lack of retraceability of the magnetisation, each cycle leads to 
the release of energy in the form of heat. In such a scenario, the larger the area of the 
hysteresis curve, the more heat is released, as seen from equation 1.2. 
 
∫= HdMfPFM 0μ  
 
Where PFM, corresponds to the loss power of the ferromagnetic particle, µ0 to the 
vacuum permeability, f to frequency of the oscillating magnetic field and the integral to 
the area of the hysteresis loop [45]. 
In macroscopic objects such as thermoseeds, this hysteretic behaviour together with 
eddy currents is responsible for heating under an oscillating magnetic field. Small 
Equation 1.2
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ferromagnetic particles, on the other hand, have most of their energy dissipated from 
hysteresis since eddy currents are negligible [45] and thus, the heating is obtained from a 
purely magnetic effect. 
In the case of nanoscaled magnetic particles, the scenario becomes different. At a 
certain size limit particles become so small that they consist of a single domain only. 
Theoretical calculations indicate that this happens for particles in the range of 15-30 nm 
for Fe, at about 70 nm for Co, and in the range of 32-55 nm for Ni [46]. At these 
dimensions, an increase in coercivity is observed in comparison to the bulk material. As 
particles become significantly smaller than this limit, however, the coercivity decreases 
until a limit where the magnetisation becomes unstable and thermal fluctuations are 
enough to change its orientation [47], a condition in which the particles are termed 
“superparamagnetic” (Figure 1.6). Below this limit; hysteresis is not observed using 
conventional magnetometry techniques as shown in Figure 1.7. 
 
Dsp Dcrt
Hc
Single 
Domain
Multi 
Domain
 
Figure 1.6. Coercivity as a function of particle size. The critical diameter (Dcrt), where 
particles have just one domain, and the superparamagnetic diameter (Dsp) are indicated. 
Reproduced from reference [47]. 
 
For superparamagnetic nanoparticles, heating under an oscillating magnetic field is 
realised by means of two different mechanisms which are illustrated in Figure 1.8. In the 
first mechanism, called Néel relaxation, the magnetic moments of the nanoparticle rotate 
within the particle in order to align with the applied magnetic field. Because the rotation is 
associated with an energy barrier, losses in the form of thermal relaxation take place 
leading to the dissipation of heat. In the second mechanism, termed Brownian relaxation, 
the magnetic moments are locked in the nanoparticle that physically rotates in order to 
have its magnetic moments parallel to the magnetic field. This physical rotation results in 
dissipation of heat by friction with the surrounding fluid. In general, the amount of heat 
 given by the superparamagnetic nanoparticles under an alternating magnetic field is given 
by: 
 
fHPSPM
2
0 χπμ ′′=  
 
Where PSPM, corresponds to the loss power in the superparamagnetic regime, µ0 to the 
vacuum permeability, f to the frequency and H to the magnetic field amplitude. The term 
χ″ encompasses the saturation magnetisation (Ms) of the nanoparticles, their volume and 
parameters related to the relaxation mode (magnetic anisotropy for Néel relaxation or 
hydrodynamic radius and fluid viscosity for Brownian relaxation) [45, 48]. 
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Figure 1.7. Hypothetic magnetisation curve of superparamagnetic nanoparticles.  
 
 
 
 
 
 
 
 
 
 
Figure 1.8. Schematic representation of Néel relaxation of nanoparticles, where the 
magnetic moment rotates within each particle and Brownian relaxation, where the 
particle rotates as a whole. Adapted from reference [49]. 
Néel Rotation
Brown Rotation
Equation 1.3 
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Experimental studies on the amount of heat that can be obtained from a given magnetic 
nanostructure is usually conducted by exposing a (colloidal) suspension of magnetic 
nanoparticles to an alternating magnetic field with a defined strength and frequency. The 
increase in temperature of the magnetic fluid under the alternating magnetic field is 
measured and the power obtained is expressed in the form of specific absorption rate 
(SAR), which is given by: 
 
dt
dTcSAR =  
 
Where c corresponds to the heat capacity of the solution and dT/dt to the initial slope 
of the time-dependent temperature curve. The SAR is a useful parameter to compare the 
heating obtained with different nanoparticles, allowing an evaluation of their suitability for 
hyperthermia. A limitation of SAR, however, is that it does not take into account the 
magnetic field amplitude and frequencies being applied. Different research groups often 
apply distinct conditions for heating, making the direct comparison of results difficult. An 
attempt to overcome this limitation was proposed very recently, with the introduction of 
the intrinsic loss power, or ILP [50], which is defined as: 
 
fH
SARILP 2=  
 
As such, the ILP eliminates extrinsic parameters which come from the device (field 
amplitude and frequency) and thus, the intrinsic heating of the nanoparticles can be 
compared. This equation is valid for superparamagnetic nanoparticles and up to 
frequencies of about 900 kHz, at which the parameter χ″ becomes frequency independent. 
As this equation was only proposed in 2009, its use is not yet widespread. 
 
1.2.3 Clinical Limits of Magnetic Fluid Hyperthermia 
 
As observed from the loss power equations, the amount of heat obtained in MFH 
increases at higher magnetic field strengths and frequencies. Thus, high field amplitudes 
Equation 1.5
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 and high frequencies would be desirable in order to increase the amount of heat dissipated 
by the nanoparticles. 
In practice, however, certain conditions can lead to discomfort to the patient and thus, 
limits exist in terms of the conditions that can be applied. These limits arise from the fact 
that time varying magnetic fields also exert forces on ions and asymmetrically charged 
molecules in tissues, resulting in electric fields and circulating currents according to 
Faraday’s law of induction. Such events might lead to consequences such as the eddy 
current heating of tissues. At the cellular level, voltages across cell membranes might be 
induced which at sufficiently high levels, can stimulate nerve cells to conduct or muscles 
to contract [51, 52].  
Studies performed by Borrelli et al. [53] show that for the human torso, the limiting 
magnetic field is of about 10 kA/m when frequencies of 10-100 kHz are considered. 
Their observations were extrapolated from experiments where time varying magnetic 
fields were applied to the hand of volunteers who reported levels which produced 
numbness or tingling. 
The first commercial system that has been built specifically for MFH operates close to 
those limits, at a fixed frequency of 100 kHz and magnetic field amplitudes of up to 
18 kA/m [54]. Clinical studies applying this device revealed that magnetic fields were 
limited by local discomfort of the patient and maximum fields that could be applied were 
of 3-6 kA/m in the pelvic region, 7.5 kA/m in the upper thorax and 10-14 kA/m in the 
head [32], which are in close agreement with the results obtained by Borreli et al.. 
Variations according to the body part derive from the fact that the power dissipated by 
eddy currents is proportional to the square of the radius of the conducting body [53]. 
 
1.3 Nanoparticles Engineered for Magnetic Fluid Hyperthermia 
 
Iron oxides have been the standard materials for magnetic fluid hyperthermia for a long 
time. The first experiments performed by Gilchrist, et al. [34] as well as the first clinical 
trials [42, 43] were conducted using nanoparticles based on this material. This is also the 
case for magnetic nanoparticles used for other biomedical applications such as magnetic 
resonance imaging. A survey of commercial contrast agents existing in 2007 [55] shows 
that they are mostly based on iron oxides, the exception being chelates of gadolinium. The 
preferential use of these materials is probably related to the wide range of synthesis 
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methods available as well as low toxicity. Nanoparticles of magnetite (Fe3O4) and 
maghemite (γ-Fe2O3) can be readily obtained by a range of methods such as 
coprecipitation, mechanical grinding and pyrolysis [56, 57]. In addition to these synthesis 
methods, biogenic nanoparticles of iron oxide have also been obtained from 
magnetotactic bacteria, living organisms that synthesise nanocrystalline magnetic 
nanoparticles in order to orient themselves along the Earth’s magnetic field. Initial studies 
have revealed considerably high SAR rates for these biogenic structures [58] and thus, 
have also attracted interest as heating agents for hyperthermia. The biocompatibility of 
iron oxides is mainly related to their biodegradability in vivo. Studies on the metabolism of 
commercial nanoparticles have shown that the iron is metabolised and incorporated into 
the body's iron store [56, 59]. 
All commercial magnetic nanoparticles which are available to date also contain surface 
modifications in order to make them more suitable for the application to which they have 
been designed. In general, surface modifications are necessary to improve the stability of 
the aqueous dispersion and avoid flocculation [32, 56, 60]. Magnetic nanoparticles used as 
contrast agents often have coatings of dextran or its derivatives [61], although studies on 
many other coatings have also been reported [60, 62]. The only commercial nanoparticle 
specifically designed for hyperthermia has an aminosilane coating, which has been 
reported to induce a preferential uptake of the particles by certain cancer cells [63, 64] 
allowing a greater accumulation in the malignant tissue. In vivo, the same particles have 
been shown to result in a more homogeneous and better interstitial distribution in the 
tumour when compared to dextran coated nanoparticles [65]. More recently, coatings 
have also been explored as a bridge to allow the conjugation of other molecules that could 
be of interest for biomedical applications, leading to multifunctional nanoparticles. That 
includes for example the conjugation of targeting moieties such as peptides and antibodies 
[66] or the conjugation of drugs [67, 68] that allows concomitant chemotherapy and 
thermotherapy. 
When the dissipation of heat upon exposure to an alternating magnetic field is 
considered, the magnetic properties of the particles must be taken into account as 
observed from the loss power equations presented in the preceding section. One possible 
way to increase the amount of heat during the therapy is to explore magnetic materials 
with higher saturation magnetisation such as metallic iron, cobalt, and alloys thereof [48]. 
Bulk magnetite and maghemite have a saturation magnetisation (Ms) of 90 Am2/kg and 
80 Am2/kg respectively whereas this property can reach 170 Am2/kg for cobalt and 
 220 Am2/kg for iron [69]. A greater dissipation of heat is of advantage since it can lead to 
a reduction in the amount of material being administered to the patient, minimising costs 
and possible side effects or, allowing the application of lower frequencies and fields, 
minimising the risks of muscular stimulation, heat arrhythmias or inductive heating of 
tissues [70] as previously discussed. 
What limits the use of those materials, however, is their low chemical stability and poor 
biocompatibility [48]. The high surface areas of metallic nanoparticles make them very 
susceptible for oxidation in ambient conditions [71] a situation that becomes even more 
severe in a physiological environment.  
An approach to overcome such drawbacks is to apply coatings that avoid reactions of 
the particle with its environment. In the case of metallic materials, an inorganic coating is 
most suitable given its higher chemical stability. Magnetic nanoparticles coated with silica, 
carbon, gold, silver and platinum have been reported [71, 72]. Carbon based coatings are 
recognised to combine high chemical and thermal stability as well as biocompatibility [71]. 
When the carbon is graphitic, an additional advantage is the many possibilities that exist 
for surface modifications, since the functionalisation of graphite structures has been 
widely explored in carbon nanotube research [73]. 
Metallic iron coated with graphite has been reported in the form of spherical structures 
[74, 75] and also in the form of wires [76, 77]. Although significant steps have been taken 
in the development of these structures, no studies have yet focused in their application for 
thermotherapy. The potential of these structures is however clear, since it combines a core 
consisting of a magnetic material of high magnetisation in combination with a chemically 
stable coat in which functionalisation with molecules of medical interest could be 
possible.  
 
1.4 Objectives 
 
New developments in nanoparticle research will undoubtedly bring a new generation of 
nanoparticles with improved properties in respect to the current iron oxides. Benefits 
might come from structures offering higher SAR rates, targeting properties and/or 
payloads such as therapeutic molecules. Carbon encapsulated nanomagnets are a class of 
particles which offer promising features towards these goals. At first, because the material 
responsible for the generation of heat is encaged inside of a stable carbon shell which 
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protects it from degradation by the human body and also protects the body from 
potential side effects originating from the magnetic material. This is especially important 
in view of high performance magnets which contain potentially toxic elements such as 
nickel and rare earth elements. Secondly, the graphite shell can be functionalised and thus 
work as an interface for conjugation with biomolecules, drugs or combinations of those, 
leading to multifunctional particles.  
Although the synthesis of such structures has already been reported, no detailed studies 
have yet been conducted on their suitability for hyperthermia neither on the potential 
functionalisation schemes that could be applied. In this work, carbon coated iron 
nanomagnets in the form of spherical particles or wires will be explored for this purpose. 
Both structures will be thoroughly characterised in order to evaluate their feasibility for 
hyperthermia in terms of magnetic properties, SAR and cytotoxicity. In order to 
investigate the possibility of obtaining multifunctional structures, surface functionalisation 
of the graphite shell will be conducted and its feasibility for the attachment of relevant 
molecules discussed. In a second step, the possibility of conjugating drugs will be assessed 
as well as the release dynamics as a function of environmental factors. Finally, the 
suitability of the functionalised nanostructures will be addressed using in vitro cell cultures 
in the form of cells grown as monolayers or as three-dimensional spheroids, a tissue 
model that better resembles the conditions found in vivo thus, validating the feasibility of 
the multifunctional nanoparticles for thermotherapy. 
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2.1 Carbon Encapsulated Iron Nanoparticles 
 
The carbon encapsulated iron nanoparticles were either in the form of spheres, obtained 
commercially from Sun Innovation's Nanomaterial Store (Freemont, USA) or in the form 
of wires, acquired from the Institute for Solid State Research of the IFW Dresden 
(Dresden, Germany) [77]. The two types of nanoparticles were obtained in the form of a 
powder. 
 
2.2 Methods for Physical Characterisation 
 
2.2.1 Transmission Electron Microscopy 
 
Morphological evaluation of the nanoparticles was carried out using a 200 keV FEI 
Tecnai G2 F-20 S TWIN high resolution transmission electron microscope (HR-TEM, 
FEI, Eindhoven, Netherlands). For sample preparation, the nanostructures were shortly 
dispersed in acetone with the help of an ultrasonic homogeniser and carefully poured over 
a standard gold mesh grid that was subsequently dried and used for analysis. 
 
2.2.2 Raman Analyses 
 
Raman spectra were acquired from nanoparticle powders with a Renishaw InVia Raman 
microscope spectrometer (Gloucestershire, UK) with a laser wavelength (λ) of 785 nm. 
Data was normalised and a second order 21 point Savitzky–Golay smoothing procedure 
was applied to reduce noise. 
 
2 
 2.2.3 X-Ray Diffraction 
 
X-Ray diffraction spectra were obtained with a Rigaku Miniflex system (Kent, England) 
with copper or cobalt radiation. The 2θ angles obtained from the equipment were 
converted to interplanar spacing using Bragg’s law: 
 
nλ = 2dsin(θ) 
 
Where n is an integer, λ the wavelength of the x-rays (1.54 Å for copper and 1.59 Å for 
cobalt), d the interatomic spacing and θ the angle between the incident ray and the 
scattering plane as obtained from the measurement. The peaks were compared with 
entries of the Powder Diffraction File 2 (PDF-2) database from the International Centre 
for Diffraction Data in order to identify the crystalline phases present in the samples. 
 
2.2.4 Magnetic Measurements 
 
Magnetic measurements of dry nanoparticle powders were conducted with a Micromag 
2900 alternating gradient magnetometer (AGM) from the Princeton Measurement 
Corporation (Princeton, USA) at room temperature and magnetic fields strengths (H) of 
up to 800 kA/m. 
 
2.2.5 Specific Absorption Rate 
 
The power dissipated by the nanoparticles was measured under an alternating current 
(AC) magnetic field generator. The system was built in-house and consisted of a high 
frequency generator with an impedance matching network and a water-cooled magnetic 
coil system. A coil with 5 turns, bore diameter of 30 mm and height of 40 mm was used 
for measurements. The setup provided AC magnetic fields with a frequency (f) of 
128 kHz and magnetic fields strengths (H) from 0 to 120 kA/m. Temperature 
measurements were obtained by means of a fiber optic temperature sensor (Luxtron One, 
LumaSense Technologies, Germany) with readings every 1 s.  
Equation 2.1 
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The heat dissipated at different magnetic field amplitudes was studied on nanoparticles 
suspended in distilled water containing 1 % high viscosity (4000 cP) methylcellulose 
(Sigma, Taufkirchen, Germany). SAR was calculated according to equation 1.4, where the 
specific heat capacity of the sample (c) was considered to be that of the solvent (water, c = 
4.118 J/gK), and normalised to the mass of nanoparticles. 
 
2.2.6 Surface Analysis 
 
X-Ray photoelectron spectroscopy (XPS) was applied to determine surface 
functionalities of the nanostructures. Spectra were obtained using a Physical Electronics 
PHI 5600 CI system (Ismaning, Germany). Monochromatic Al Kα X-rays (350 W) were 
used for excitation and a hemispherical analyser with an acceptance diameter of 800 µm 
working at pass energy of 90 eV (survey spectra) or 29 eV (detail spectra) was used for 
electron detection. 
For the qualitative evaluation of carboxylic functionalities, a method using ultraviolet 
visible (UV-Vis) spectroscopy was applied [78]. The procedure is based on the 
decomposition of 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) upon reaction 
with carboxylic acids. In aqueous solutions, EDC is stable for a period of a few hours and 
has a specific absorption peak at about 220 nm. In the presence of compounds containing 
carboxyl groups EDC reacts and a time dependent reduction in the intensity of its 
absorption peak is observed as it is consumed. The rate of decay in the intensity was used 
as an indication of the density of carboxylic groups in the samples. In a typical 
measurement, 2 mg of nanoparticles were suspended in 2 ml of a freshly prepared 
solution of 1 mM EDC (Sigma) in a buffer of 2-(N-morpholino)ethanesulfonic acid 
(MES, Sigma) at a pH of 5.5 (adjusted with dilute sodium hydroxide (NaOH)). After 1 
minute, the particles were precipitated with a magnet and the absorption of the 
supernatant was measured in an UV-Vis spectrophotometer (Ultrospec 3000, GE 
Healthcare, Munich, Germany) at 224 nm. After the measurement, the nanoparticles were 
immediately resuspended by shaking. This process (precipitation of the nanoparticles, 
absorbance measurement and resuspension) was repeated every five minutes for up to 1 
hour. The normalised decrease in absorbance with time was used as an indication of EDC 
loss after reacting with carboxyl groups on the nanoparticle surface. 
 
 2.3 Surface Functionalisation 
 
2.3.1 Acidic Treatments 
 
Acidic treatments were performed with dilute solutions of analytical grade hydrochloric 
acid (HCl), nitric acid (HNO3), sulphuric acid (H2SO4) or combinations of those. In a 
typical run, 100 mg of the nanoparticles were immersed in the acid solution, dispersed in a 
bath sonicator for 5 min (USR 9, Merck Eurolab, Darmstadt, Germany) and heated up to 
the treatment temperature (120 oC or 60 oC) on a Monotherm hot plate (Faust, 
Meckenheim, Germany). After the treatment period, the nanoparticles were precipitated 
with a magnet, the remaining supernatant was removed with a pipette and the 
nanoparticles were then resuspended in distilled water by shaking. This process 
(precipitation the nanoparticles, removal of supernatant and resuspension in water) was 
repeated several times in order to wash away any reaction products and the remaining 
acid. 
After the final washing step the remaining material was dried overnight at 60 oC and its 
mass measured in an analytical balance (R200D, Sartorius, Göttingen, Germany). The 
values obtained were used to quantify the amount of material lost (leached) as a 
consequence of the acidic treatments.  
 
2.3.2 Chemical Conjugation via Diimide-activated Amidation 
 
Covalent conjugation of molecules to the nanoparticles was performed via diimide-
activated amidation. Two types of chemicals were conjugated: in the first studies 
methylamine (Sigma) was used as a model molecule and in a second step, a fluorescent 
probe (Promofluor-633 amino-modified, PromoCell, Heidelberg, Germany) was applied.  
In the first case, a 60 mM solution of methylamine was prepared in 50 mM MES buffer 
and the pH adjusted to 5.5 with dilute HCl (in contrast to pure MES which is acidic, 
methylamine is very basic and requires an acid for pH adjustment). Two milligrams of 
nanoparticles were suspended in 1 ml of this solution by sonication in a Bandelin 
HD2070 ultrasonic homogeniser (Berlin, Germany) and fresh EDC was added to a final 
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concentration of 52 mM. The solution was allowed to react on a platform rocker for 2 h 
at room temperature and the nanoparticles were subsequently washed as previously 
described (successive steps of magnetic precipitation, supernatant removal and 
resuspension in distilled water). A second sample was prepared under the same conditions 
but without the addition of EDC to be used as a negative control where the conjugation 
reaction should not take place.  
A similar procedure was applied for the fluorescent probe except that instead of 
methylamine, the amino-modified dye was used at a concentration of 130 µM. Also for 
this condition, a negative control without the addition of EDC was prepared. Removal of 
the adsorbed dye was accomplished by the previously mentioned washing steps, where 
instead of water, cell culture medium was used. Fluorescent reading of the nanoparticles 
was performed in a Fluostar Omega multidetection microplate reader (BMG Labtech, 
Jena, Germany) from 96-well plates containing 10 µg of nanoparticles suspended in 100 µl 
of water containing 1 % high viscosity methylcellulose. 
 
2.4 Drug Conjugation and Platinum Measurements 
 
2.4.1 Aquation of Cisplatin 
 
Aquated cisplatin (cis-diamminedichloroplatinum(II), CDDP) was used for studies 
involving drug conjugation. The aquation procedure involved mixing an aqueous solution 
of CDDP (Sigma) with AgNO3 (Caelo, Hilden, Germany) in a 1:2 molar ratio and placing 
it overnight on a platform rocker protected from light. This procedure allows the 
abstraction of the chloro ligands from the drug and its precipitation in the form of AgCl. 
The solution was then centrifuged for 30 minutes at 3000×g to concentrate the 
precipitate. The supernatant (aquated CDDP) was used for nanoparticle conjugation.  
 
2.4.2 Drug Loading and Release 
 
For CDDP conjugation, the nanoparticles were suspended in a solution containing 
100 µg/ml of aquated CDDP. The mass ratio of nanoparticle to drug was of 10:1. The 
 suspension was protected from light and placed on a platform rocker for 24 h. After this 
period, the nanoparticles were washed twice with distilled water to remove unreacted 
CDDP. 
The drug release was studied in water or saline solutions at 37 oC. For that purpose, 
2 mg of nanoparticles freshly loaded with CDDP were suspended in 500 µl of water or 
0.9 % saline solution. At different time intervals the nanoparticles were precipitated with a 
magnet and the 500 µl of supernatant were taken for platinum quantification. The 
nanoparticles were then resuspended in 500 µl of fresh solution and the procedure 
repeated at several time points from which a cumulative drug release curve was obtained. 
The effect of heating on the drug release was studied by suspending 500 µg of 
nanoparticles freshly loaded with CDDP in 500 µl of saline. The suspension was 
incubated for 30 minutes in an ice bath (4 oC), or on a heating block (37, 43 or 50 oC). 
After this period, the nanoparticles were precipitated with a magnet and the saline 
solution analysed for platinum quantification. 
 
2.4.3 Quantification of Platinum 
 
Cisplatin was quantified by measuring the amount of platinum in the samples since each 
drug molecule contains a platinum atom. A slightly modified colorimetric assay based on 
the reaction of platinum with o-Phenylenediamine (OPDA) [79] was applied. For that 
purpose, 500 µl of a CDDP containing solution were mixed with the same volume of 
1.4 mg/ml OPDA (Sigma) dissolved in dimethylformamide (Merck, Darmstadt, 
Germany). The mixture was heated in a heat block at 100 oC for 10 minutes and then 
cooled in an ice bath for a further 10 minutes after which it was transferred to a 
poly(methyl methacrylate) cuvette (Brand, Wertheim, Germany) for absorbance 
measurement in an UV-Vis spectrophotometer (Ultrospec 3000, GE Healthcare). 
Absorbance was measured against a water blank at three wavelengths (600, 720 and 
800 nm). The absorbance at 720 nm corresponds to the maximum peak of the reaction 
product. Values at 600 and 800 nm were taken for baseline correction. Absolute values of 
cisplatin were calculated from a calibration curve obtained from solutions with known 
concentrations of CDDP. 
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2.5 Cell Culture and Biological Assays 
 
2.5.1 Cell Culture 
 
Cell culture studies were performed with the prostate cancer cell line DU-145 
(American Type Culture Collection, Wesel, Germany) and foreskin fibroblasts 
(Department of Pediatrics, TU Dresden, Dresden, Germany). All experimental work 
involved culture medium consisting of Dulbecco’s Modified Eagle’s Medium (DMEM) 
supplemented with 10 % fetal calf serum, 1 % HEPES buffer, 1 % MEM non-essential 
amino-acids and 1 % streptomycin/penicillin (all from Invitrogen, Karlsruhe, Germany).  
For routine culture, cryopreserved cells were thawed, washed twice with culture medium 
to remove cryoprotectants and seeded into 75 cm2 culture flasks containing 15 ml of 
culture medium. Cells were always allowed to grow at 37 oC in a humidified 5 % CO2 
incubator.  
Regular cell passaging was performed when cell density reached 80-90 % of the flask 
growth surface. Cells were passaged up to 30 times. After the 30th passage, a new culture 
from cryopreserved cells was started. The passaging protocol involved two washing steps 
with phosphate buffered saline (PBS, PAA Laboratories, Cölbe, Germany), trypsinisation 
with trypsin/EDTA (Invitrogen) and resuspension in culture media. After the last step, a 
fraction of the cells was taken for seeding into a new flask. 
For three-dimensional culture involving spheroids, a fixed number of cells (typically 
5×103 or 10×103) were seeded in U-bottom 96-well plates. To avoid their attachment to 
the plate, low viscosity (15 cP) methylcellulose (Sigma) was dissolved in DMEM 
beforehand and added to the medium to a final amount of 0.25 %. After a period of 7 
days spheroids were formed and stable enough for manipulation. At this stage they were 
transferred to culture plates containing a layer of 1 % agarose (Serva, Heidelberg, 
Germany) with a volume of 50 µl and allowed to grow for 7 more days before being used 
for experimental studies (Figure 2.1). Spheroid size was monitored by taking images with a 
digital camera at a resolution of 1600x1200 pixels followed by size measurement with 
ImageJ software [80]. Two orthogonal diameter measurements were obtained from at 
least 5 spheroids from which the volume was calculated considering a spherical shape. 
 
 Cell Seeding Transfer to Agarose 
Coated Plates
Spheroid
Formation  
 
Figure 2.1. Schematic representation of the steps involved in spheroid formation. 
 
2.5.2 Toxicity Studies 
 
Cytotoxicity was evaluated by measuring changes in the metabolic activity of the cells 
after exposure to the nanoparticles or drugs. Measurements were made employing the cell 
proliferation reagent WST-1 (Roche, Mannheim, Germany), which is based on the 
cleavage of the tetrazolium salt WST-1 by mitochondrial dehydrogenases producing a 
water soluble formazan dye. Since this reaction relies on the mitochondrial respiratory 
chain (NADH production), the amount of formazan dye produced is proportional to the 
number of viable (healthy) cells. In a typical experiment, cells were harvested from their 
culture flasks and then seeded overnight in 96-well plates with a density of 7.500 cells per 
well. On the next day the culture medium was removed and replaced with 100 µl of 
medium containing the compound of interest (nanoparticles or drugs) at different 
concentrations. In order to stabilise the nanoparticles during the incubation period, those 
were suspended in culture medium containing 1 % high viscosity (4000 cP) 
methylcellulose (Sigma). For the cytotoxicity evaluation of cisplatin, the drug was diluted 
directly in the culture medium. After the incubation period (24 h or 72 h depending on 
the experiment) the media was aspired from the wells, the cells were washed twice with 
200 µl of PBS and finally incubated with 100 µl of fresh medium. After the addition of 
fresh medium, WST-1 reagent was immediately added to the cells (10 µl per well) and 
colour development was followed for up to 60 minutes. Absorbance was measured in an 
ELISA reader (Anthos Microsysteme, Krefeld, Germany) at 450 nm and 620 nm (the later 
as reference). Measurements were performed in quadruplicate and normalised to control 
(untreated) cells. A sigmoidal curve was fitted to the data using commercial software 
(Origin, Originlab, Northampton, USA) from which the half maximal inhibitory 
concentration (IC50) values were calculated.  
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Studies involving the cytotoxicity to spheroids were performed with 8 replications. 
Spheroids were typically incubated with 150 µl of the test solution, leading to a total 
volume of 200 µl in the culture well (50 µl from the agarose layer). After the washing step, 
spheroids were incubated with 50 µl of fresh medium only to account for the agarose 
layer (another 50 µl) and then 10 µl of WST-1 agent were added. Colour development was 
monitored for up to 6 h in the case of spheroids. 
Release of iron ions by the nanoparticles in aqueous solutions was measured using the 
“Iron Assay Kit” for quantitative colorimetric determination of iron (BioChain, 
Heidelberg, Germany). The nanoparticles were dispersed in 0.9 % saline solution at a 
concentration of 5 mg/ml and at different time intervals precipitated with a magnet. The 
supernatant was removed and stored for later iron quantification with the assay kit 
according to the manufacturer’s instructions. The nanoparticles were then resuspended in 
the same amount of fresh saline solution. The procedure was repeated at several time 
points (1, 4, 11, 18, 25 and 32 days) from which the cumulative iron release was 
calculated. 
 
2.5.3 Thermotherapy Studies 
 
The effects of thermotherapy were studied with cell suspensions and spheroids. In the 
first case, the clonogenic survival method was applied to access cytotoxicity. For that 
purpose, a total of 2×104 cells were harvested and suspended in 300 µl of culture medium 
containing 1 % of high viscosity methylcellulose and the nanoparticles at a concentration 
of 5 mg/ml. Three of such suspensions were prepared, where one was simply kept at 
37 oC for 30 minutes. The other two samples were exposed to an alternating magnetic 
field with H = 60 kA/m and f = 128 kHz with the same setup as described in section 
2.2.5 until the temperature reached 43 oC or 48 oC. Once the treatment temperature was 
reached the magnetic field was controlled in order to keep the temperature stable during 
the treatment period (30 min). After the treatment 2 µl of each sample (equivalent to 130 
cells) were added to 6-well plates in triplicate and the cells were cultured for 8 days to 
allow the formation of colonies. Untreated cells were also plated under the same 
conditions as a control sample. After the colony formation period, cells were washed with 
PBS, fixed and stained with 5% Giemsa (Merck). Macroscopic colonies were counted and 
 results were normalised to the control sample. Statistical significance between control and 
treated cells was assessed with a two tailed paired Student’s t-test.  
For the spheroids, thermotherapy studies were conducted in two steps. In a first stage, 
the general effects of heat on metabolic activity were assessed simply by heating the 
spheroids in a water bath. Spheroids were harvested from the 96-well plates, pooled 
together in a micro test tube (Eppendorf, Wesseling, Germany) and then heated at 
different temperatures for 30 minutes with a Julabo F25-HC precision water circulator 
(Julabo, Seelbach, Germany). After the thermotherapy treatment, spheroids were 
transferred back to agarose coated 96-well plates and further incubated at 37 oC for 24 h, 
48 h or 72 h when the metabolic activity was assessed with the WST-1 reagent as 
previously described. In the second phase of the studies nanoparticles were used for 
heating. Spheroids were harvested and pooled together in micro test tubes with 16 
spheroids each. The culture medium was aspired and then replaced with medium 
containing 1 % high viscosity methylcellulose and the nanoparticles at a concentration of 
5 mg/ml. Samples were kept at 37 oC or heated up to 43 oC or 48 oC as previously 
described and kept at these temperatures for 30 minutes. After the thermotherapy 
treatments spheroids were thoroughly washed with culture medium to remove excess 
nanoparticles and then transferred individually to 96-well plates containing an agarose 
layer. For each condition, 8 spheroids were used for the measurement of metabolic 
activity after 72 h whereas the other 8 spheroids were cultured for 24 more days while 
their growth was monitored.  
 
2.5.4 Cell Cycle Measurement 
Cell cycle distribution was determined using the “Cycletest Plus DNA Reagent Kit” 
(BD-Biosciences, Heidelberg, Germany). The method is based on the measurement of the 
amount of DNA present in the cells by flow cytometry and was carried out according to 
the manufacture’s instructions. In brief, the measurement is performed by permeabilising 
the cells followed by a subsequent incubation with propidium iodide, which binds 
stoichiometrically to DNA. About 13.000 cells are then analysed by flow cytometry and 
discriminated by fluorescent intensity as follows:  
 
• Cells in G1 stage: standard fluorescent intensity 
• Cells in S phase: intermediate fluorescent intensity 
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• Cells in G2 and M stage: double fluorescent intensity 
• Apoptotic cells: fluorescent intensity lower than standard, due to DNA 
degradation 
Data acquisition was performed with a FACScan (BD-Biosciences) and data analysis 
with the software ModFit LT (Verity Software House). 
 
2.5.5 Imaging Techniques 
 
Scanning electron microscopy (SEM) images of the spheroids were obtained with a 
NanoSEM system (FEI, Kassel, Germany). For sample preparation, spheroids were 
harvested, washed with PBS, fixed with 4 % neutral buffered paraformaldehyde (SAV-LP, 
Flintsbach, Germany), dehydrated in an alcohol series (70 % - 95 %), dried in air and 
finally sputtered with gold. Topographic images were obtained from secondary electrons 
(SE). 
Fluorescent studies were conducted using a Leica TCS SP5 system. For preparation of 
monolayer slides, cells were seeded overnight in 4-well chamber slides (BD-Biosciences) 
and then incubated with the fluorophore-conjugated nanoparticles suspended in culture 
medium containing 1 % high viscosity methylcellulose. After the incubation period, the 
following protocol was applied for sample preparation (all steps performed with the 
samples protected from light): 
 
1. Two washing steps with PBS 
2. Fixation with 4 % neutral buffered paraformaldehyde for 10 minutes 
3. Two washing steps with PBS  
4. Permeabilisation with 0.5 % triton X-100 (Serva, Heildelberg, Germany) for 10 
minutes 
5. Two washing steps with PBS 
6. Blocking with 3 % bovine serum albumin (Sigma, Taufkirchen, Germany) to 
avoid non-specific protein interactions 
7. Two washing steps with PBS 
8. Incubation with PromoFluor488-labelled phalloidin (PromoCell, Heidelberg, 
Germany ) for actin staining according to manufacturer’s instructions 
9. Two washing steps with PBS 
 10. Incubation with DAPI (Dako, Hamburg, Germany) for nuclei staining 
according to manufacturer’s instructions 
11. Two washing steps with PBS 
12. Slide mounting with PromoFluor antifade reagent according to manufacturer’s 
instructions. 
 
For histological analysis of spheroids, those were first fixed and dehydrated in the same 
manner as for SEM preparation. After these steps, molten paraffin was poured over the 
spheroids and kept at 65 oC for 30 minutes until they were cooled down to room 
temperature. The paraffin block containing the spheroids was then sectioned with a 
microtome (HM 440E, Micron, Walldorf, Germany) from which 5 µm slices were 
obtained. The paraffin slices were mounted on a microscope slide, treated with xylol for 
removal of paraffin and rehydrated with an alcohol series with progressive increases in the 
amount of water. The sections were then stained with haematoxylin and eosin (Merck) 
according to standard protocols [81], mounted with Entellan (Merck) and analysed in an 
optical microscope (Axioskope 2, Carl Zeiss, Göttingen, Germany). 
1
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 FEASIBILITY STUDY OF TWO CARBON ENCAPSULATED 
IRON NANOSTRUCTURES FOR MFH 
 
 
3.1 Physical Properties 
 
The potential application of carbon coated iron nanoparticles for thermotherapy relies 
on an adequate encapsulation of the metallic nanoparticle within the carbon shells. The 
encapsulation provides a protection of the iron core against reactions with its 
environment thus, preserving its properties and avoiding potential adverse reactions of 
tissue with the metallic material. Structures which have been synthesised so far consist of 
iron nanospheres [74, 75] or iron nanowires [76, 77] encapsulated with a graphite coat. 
The commercial iron nanospheres (FeNS) used in this study consist of iron cores with an 
average diameter of 25 nm (as stated by the supplier) surrounded by 3-5 graphene layers 
(single layers of graphite) as observed by electron microscopy (Figure 3.1a,b). Iron 
nanowires (FeNW), on the other hand, consist of longer structures, on the order of 
100-300 nm in length and are surrounded by up to 30 graphene layers (Figure 3.1c,d). The 
coat encapsulating the nanowires is often longer than the nanowire itself (Figure 3.1c) 
leading to tubes with empty voids as observed in the image. 
To confirm the nature of the coat, the materials were analysed by Raman spectroscopy. 
This technique as been proven useful for the analyses of carbon nanostructures, in special 
carbon nanotubes (CNTs), as it can provide a multitude of information such as the 
number of graphene layers, the presence of structural defects, the diameter of nanotubes, 
its chirality and the metallic state, among others [82]. Here, the technique is applied to 
investigate the presence of graphite and estimate the density of structural defects. This is 
based on the fact that graphite structures often present two characteristic peaks in the 
spectra; one at about 1580 cm-1 corresponding to a signal originating from the graphite 
structure (G-band) and one at about 1350 cm-1 corresponding to disordered graphite (D-
band). In general, the ratio of the intensity of these peaks can be taken as an indication for 
the quality of the samples, where the lower the ID/IG ratio, the more ordered the graphene 
layers are and fewer defects are present in its structure. Both samples clearly show both 
bands as indicated in Figure 3.2, demonstrating the presence of carbon in the form of 
3 
 graphite. The disorder peak of the FeNS is notably higher than for FeNW with the ID/IG 
ratios amounting to 1.08 and 0.75 respectively, indicating a higher number of defects in 
the shell of the spherical nanomagnets. Another clear difference between the spectra of 
the two structures are the broader bands observed in the FeNS and the lack of the 
overtone peak of the D band (G’), which is commonly observed at 2600 cm-1 in graphitic 
materials. These characteristics are an indication of a lower ordering of the graphite [83] 
and have also been observed in the graphite shell of copper [84] and cobalt [85] 
nanoparticles.  
 
 
 
 
Figure 3.1. Micrographs of the different carbon encapsulated iron nanoparticles as 
observed by TEM. (a) overview of FeNS, (b) detailed view of single nanospheres (carbon 
shells indicated by arrows), (c) overview of FeNW (the white and gray arrows indicate a 
nanowire and an empty carbon shell respectively), (d) detailed view of a single nanowire. 
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Figure 3.2. Raman spectra of FeNS and FeNW. The graphite (G) and  
disorder (D) peaks are indicated in the Figure as well as the overtone peak of the D band (G’). 
 
In addition to the shell structure, the core properties are also of importance. This 
concerns mainly the fact that iron can be found in two crystalline structures, one of which 
is not ferromagnetic. At high temperatures (above 910 oC) iron is found in its face 
centered cubic structure (fcc-iron or γ-iron) which is paramagnetic. At low temperatures 
(bellow 910 oC) the thermodynamically stable phase of iron is ferrite, which has a base 
centered cubic structure (bcc-iron or α-iron) and is ferromagnetic. Concerning the 
magnetic properties, only the later would be suitable for magnetic hyperthermia. X-ray 
powder diffraction was applied to qualitatively evaluate the presence of these crystalline 
structures. Analysis of the powders reveals that FeNS consists mainly of α-iron whereas 
FeNW consists of both crystalline phases as indicated in Figure 3.3. As such 
nanostructures are synthesised in processes involving high temperatures such as arc 
discharge [74, 75], thermolysis [76] and chemical vapor deposition [77], the remaining 
γ-iron found in the FeNW could be a metastable phase formed upon rapid cooling during 
synthesis. Ideally, however, the amount of α-iron in the core should be maximised. 
Although annealing treatments at lower temperatures could allow the transformation of 
the metastable fcc-iron to bcc-iron, the lattice (volume) expansion associated with this 
transformation often results in the partial destruction of the graphite coat [86], limiting 
the possibility of increasing the relative amount of ferromagnetic iron. 
  
 
Figure 3.3. X-Ray diffraction pattern of FeNS and FeNW. The peaks indicated by circles 
(●) and squares (■) originate from bcc- and fcc-iron respectively. 
 
Taken together, these results indicate that FeNW have a very limited amount of 
magnetic iron when compared to the FeNS. Several factors appear to be responsible for 
that. At first, FeNW are often short, but with very long carbon shells leading to empty 
voids which do not consist of iron. Secondly, this structure has a large number of carbon 
shells (thick coat). These two characteristics result in a high amount of carbon in relation 
to iron. FeNS, on the other hand, are more compact, with a core comprised fully of iron 
and a smaller number of shells which increases the relative amount of iron in the sample. 
Furthermore, the FeNW have a considerable amount of iron in the paramagnetic fcc 
structure, which is not of relevance for hyperthermia. These findings are reflected in the 
magnetic properties (Figure 3.4) which show that FeNW have a much lower saturation 
magnetisation (13 Am2/kg) and thus, a lower relative amount of magnetic iron when 
compared to the FeNS (150 Am2/kg). If the saturation magnetisation of bulk bcc-iron 
(220 Am2/kg) [69] is taken as a reference to quantify the amount of iron the samples, its 
relative amount can be estimated to be of 6 % for the FeNW and 68 % for the FeNS. In 
both cases hysteresis was observed, with the remanent magnetisation amounting to 30 and 
4 Am2/kg and the coercivity to 15 and 45 kA/m for the FeNS and FeNW respectively. 
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Figure 3.4. Magnetisation curves of FeNS and FeNW at room temperature. 
 
3.2 Specific Absorption Rate 
 
The importance of having a high relative amount of magnetic material in the 
nanoparticles is ultimately related to the amount of heat that is dissipated under an 
alternating magnetic field, making their application for magnetic thermotherapy feasible. 
For this reason, the SAR of the two carbon encapsulated nanostructures were measured 
under AC magnetic fields. Here, the nanostructures were dispersed in distilled water 
containing 1 % methylcellulose, an additive that increases the viscosity of the solution. 
That was necessary in order to avoid sedimentation of the nanoparticles which was 
significant during the time course of the measurement when suspended in water only. 
The large differences in the amount of magnetic iron in the samples were reflected in 
the SAR (Figure 3.5), where values for the FeNW were marginal when compared to 
FeNS. Under the conditions applied in the measurement, heat dissipation was only 
detected at fields above 30 kA/m and at the highest magnetic fields (90 kA/m), it reached 
values of 240 W/g and 19 W/g for the FeNS and FeNW respectively. It must be noted 
that the presence of hysteresis as observed in Figure 3.4 does not necessarily imply that 
heat is dissipated in the form of hysteresis losses. In the measurements of magnetisation 
curves, the nanoparticles are immobilised on a substrate which restricts their physical 
rotation via Brownian relaxation. This condition changes when the nanoparticles are 
 dispersed in aqueous solutions, where their rotation becomes possible as it has been 
shown for FeNW [87] and other magnetic particles [88]. This situation is probably realised 
for the FeNS too, and the fact that the SAR displays a quadratic dependence on the field, 
as expected for relaxation losses (Equation 1.3), supports the hypothesis that heating is 
achieved by these mechanisms. If the heating is assumed to originate from relaxation 
losses only, the SAR values can be converted to the respective ILP of the particles. In that 
case, the FeNS and the FeNW would have an ILP of 0.23 and 0.02 nHm2/kg respectively. 
A comparison of 16 types of nanoparticles based on iron oxides by Kallumadial et al. [50] 
has shown that their ILP ranges from 0.15 to 3.12 nHm2/kg, indicating that the FeNS 
values are in the lower limit when compared to those structures. FeNW, on the other 
hand, have a much poorer performance in terms of heat dissipation. 
 
 
 
Figure 3.5. SAR of FeNS and FeNW as a function of magnetic field strength. Values 
were measured in an aqueous suspension of nanoparticles with a concentration of 5 mg/ml 
and at a frequency of 128 kHz. Dashed lines correspond to the quadratic fit of the data. Inset: 
temperature evolution of FeNS at 40 kA/m as an example of a typical heating curve from 
which the SAR is calculated. 
 
3.3 Iron Release and Cytotoxicity 
 
When medical applications are considered, the biocompatibility of the structures is of 
relevance. The safety of nanoparticles in particular has been widely discussed given their 
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different properties when compared to their macroscopic counterparts. Because of their 
small size and high surface area very particular effects are observed in vitro and in vivo. 
Their reduced dimension, for example, makes their cellular uptake and translocation to 
secondary organs easier than it is for larger particles. The large surface area, on the other 
hand, makes protein and lipid adsorption very effective, altering biokinetics [89]. The 
potential toxic effects that could arise because of such characteristics have actually lead to 
the establishment of a new field of study denominated nanotoxicology [90].  
When carbon nanostructures such as fullerenes and carbon nanotubes are considered, 
extensive studies have been performed in the past years, and considerable research was 
published on their biocompatibility. Recent reviews [91-93] however, point out that 
results are often inconsistent and no clear consensus exists for the biocompatibility of 
these structures. An agreement in those studies is however, that the difficulty in assessing 
the biocompatibility of carbon nanostructures derives at least in part from the variability 
between samples. The degree of aggregation and presence of surface functionalities 
appear to influence the outcome when biocompatibility studies in vitro are considered. In 
the case of CNTs, even more variables exist such as the type (single or multiwalled), the 
length and respective aspect ratio as well as the presence of catalyst particles resulting 
from the manufacturing process. 
Those considerations are of relevance for the structures in question since the FeNS and 
FeNW resemble a fullerene and CNT respectively. The core of these nanostructures is 
also pertinent when cytotoxicity is discussed since they consist of iron. Although iron is 
essential for life, being involved in oxygen transport and in the activity of several enzymes, 
its regulation must be carefully balanced since its overload might lead to oxidative stress 
and cancer [94, 95]. For that reason, the release of iron from the nanoparticles in saline 
solution was measured as a first step towards identifying potential toxic characteristics. 
Incubation of the nanomagnets in saline for up to 32 days resulted in no detectable 
amounts of iron release from either structure thus, evidencing that the metal is well 
encapsulated in the carbon shells.  
In order to complement these studies, the direct cytotoxicity of these two 
nanostructures was measured in vitro. Prior to those studies, however, a strategy for their 
suspension in cell culture medium was developed since nanoparticles in general tend to 
strongly aggregate in aqueous solutions. This situation was overcome by adding 1 % high 
viscosity methylcellulose to the culture medium as an additive. This compound is known 
to display a very good biocompatibility, being used as an additive in food and 
 pharmaceutical industries as well as in cell culture [96-98] and thus, does not interfere with 
cell growth and metabolism. The effect of methylcellulose in stabilising the nanoparticle 
suspension is illustrated in Figure 3.6, where solutions with a concentration of 100 µg/ml 
are shown after being freshly prepared or 24 h after preparation. The fresh suspensions 
have a dark color because of the suspended nanoparticles, the FeNW being noticeable 
darker. This is a result of the lower amount of iron in this structure, resulting in a lower 
overall density and thus, a higher number of particles for the same mass and 
concentration in respect to FeNS. The aggregation and precipitation of the nanostructures 
at the bottom of the flasks is clearly observed when methylcellulose is not used. From 
these images, it is understandable that if the nanoparticles were applied for cell culture 
studies without an additive to aid their suspension, concentration gradients in the culture 
dishes and sedimentation of high amounts of nanoparticles directly over the cells would 
take place. 
  
 
 
Figure 3.6. Effect of methylcellulose on the stability of nanoparticle suspensions. 
Upper panel corresponds to images of particles which have been freshly suspended at a 
concentration of 100 µg/ml and the bottom panel to the same suspensions after a period of 
24 h. (a) FeNW in culture medium, (b) FeNW in culture medium with 1 % methylcellulose, 
(c) FeNS in culture medium, (d) FeNS in culture medium with 1 % methylcellulose. 
 
The cytotoxicity of the nanoparticles was evaluated by measuring changes in cell 
viability after 24 h exposure to increasing concentrations of the two different 
nanostructures. Two different cell lines were applied for those studies. Fibroblasts were 
used as model of non-malignant cells whereas the prostate cancer cell line DU-145 was 
used as a model of malignant cells. It is important to call attention to the fact that 
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although these nanoparticles are aimed at the treatment of cancer, neither of the cell types 
should display a toxic response to them. A toxic response leading to cell death is only 
desired when the nanoparticles are used for the treatment modality in question, which is 
thermotherapy. When the biocompatibility of the material itself is considered, no cell 
should display a toxic response.  
 The measurements were carried out with relatively high concentrations of FeNS and 
FeNW, up to a maximum of 1000 µg/ml. As a positive control, dimethyl sulfoxide 
(DMSO) was used. Although this substance does have a range of medical and biological 
applications [99] its use is limited to relatively small concentrations since high doses are 
known to be toxic. Figure 3.7 shows the relative viability (metabolic activity of the sample 
normalised to untreated condition) of DU-145 cells after exposure to the concentration 
range applied in this study. A clear dose dependent decay in viability is seen for the 
positive control, showing the suitability of the method to evaluate cytotoxicity. Exposure 
to FeNS and FeNW, on the other hand, exhibited only marginal toxic effects, with a slight 
decay in viability only at the highest concentrations. Remarkably, the IC50 was not reached 
even though concentrations as high as 1000 µg/ml were applied. 
 
 
 
Figure 3.7. Relative viability of DU-145 cells after incubation with FeNS, FeNW or 
DMSO. Cells were seeded in 96-well plates, exposed to the compounds for 24 h, washed with 
PBS and incubated with the WST-1 reagent for up to 60 minutes. Results shown are the mean 
of measurements performed in quadruplicate and normalised to untreated cells. Error bars 
represent standard deviation and the dashed line corresponds to the sigmoidal fit of the data. 
 
Similar results were obtained for fibroblasts. As observed in Figure 3.8, DMSO also 
resulted in a gradual decay in viability whereas FeNS and FeNW had only marginal 
 effects. A particularity in the case of this cell line was a slight increase in viability when 
exposed to the highest concentrations of FeNW (500 and 1000 µg/ml). These results arise 
from the fact that even with the use of methylcellulose, a small amount of FeNW still 
sediments over the cells and tend to adhere strongly to their membrane. Even when 
rinsed with PBS to remove excess particles, a procedure applied immediately before the 
viability measurement, a small amount still stays over the cells at those concentrations 
resulting in slightly higher absorbance readings and consequently, to this artefact. 
 
 
 
Figure 3.8. Relative viability of fibroblasts after incubation with FeNS, FeNW or 
DMSO at different concentrations. Cells were seeded in 96-well plates, exposed to the 
compounds for 24 h, washed with PBS and incubated with the WST-1 reagent for up to 60 
minutes. Results shown are the mean of measurements performed in quadruplicate and 
normalised to untreated cells. Error bars represent standard deviation and the dashed line 
corresponds to the sigmoidal fit of the data. 
 
Although positive results have been obtained in vitro, the structure of the FeNW should 
be additionally discussed in light of recent animal studies that have been reported on the 
toxicity of CNTs. These structures have a particular characteristic which is their high 
aspect ratio since they exhibit a diameter of a few nanometers and lengths that can reach 
up to several micrometers. It has been suggested that this trait might lead to an in vivo 
pathogenicity similar to asbestos; fibre materials that in the past caused a global pandemic 
of lung diseases during exposure in mining and industry [100]. In vivo toxicological studies 
involving mice and rats indicate that this effect is likely to be more severe for long 
nanotubes (several micrometers) or big aggregates of shorter ones [100-102]. The 
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pathogenicity in those cases is likely to be a consequence of frustrated phagocytosis, 
where the long fibres cannot be engulfed by phagocytes leading to inflammation and 
formation of granulomas [100, 103]. Given that FeNW consist of iron nanowires 
encapsulated in carbon shells of several micrometers in length, such risks must be also 
taken into account when their medical applications are considered.  
 
3.4 Implications on the Potential Use for Thermotherapy  
 
The structural comparison of the FeNS and FeNW has shown that both materials 
consist of iron particles which are encapsulated by graphite thus, delivering the 
characteristics that were looked for in this work in terms of having a metallic nanoparticle 
which is protected from its environment by an inert carbon shell. The proper 
encapsulation was reinforced by the results which have shown no release of iron ions 
when in saline solutions. When it comes to their application for thermotherapy, however, 
the magnetic properties and SAR are of great importance and in this aspect, the FeNW 
have shown a poor performance when compared to the FeNS. These results can be 
credited to at least three factors. At first, to an inefficient filling of the cavity of the carbon 
shell, that was partially empty. Second, to the carbon shell of this structure, which was 
very thick thus resulting in a lower amount of iron per mass of material. This leads to 
lower SAR and saturation magnetisation, properties which are normalised to the mass. 
Third, the iron present in the structure was largely in the form of γ-iron, which is not 
ferromagnetic.   
When tested in cell culture, both nanostructures have shown to be well tolerable. The 
method used to assess cytotoxicity gives a direct reading of cell viability in respect to a 
control condition, showing that no death has occurred when exposed to up to 
1000 µg/ml of either material. It must be taken into account; however, that this 
measurement does not consider other effects that might play a role in their 
biocompatibility such as oxidative stress. As a first screening method in order to assess 
the overall cytotoxicity of the structures, the WST-1 assay is however adequate and shows 
that both structures are well tolerable in cell culture. It is however important to note the 
morphological characteristics of the FeNW in light of recent results which have been 
recently obtained for CNTs and the potential risk that their long length could have in 
terms of resembling asbestos.  
 Taken together, these findings show that FeNS are the most promising structure in 
terms of their application for thermotherapy and will therefore be the focus of the work 
discussed in the next chapters. In order for FeNW to be feasible for such therapy, 
improvements in the synthesis methods would be necessary in order to increase the 
relative amount of ferromagnetic iron and thus, the amount of power (heat) that could be 
potentially dissipated under an alternating magnetic field.  
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 SURFACE FUNCTIONALISATION OF CARBON 
ENCAPSULATED NANOSPHERES 
 
4.1 Effect of Acidic Treatments on Magnetic and Surface Properties 
 
4.1.1 Assessment of Suitable Conditions for Surface Oxidation  
 
One of the advantages of having graphite as the encapsulating shell of the metallic iron 
nanoparticles is their potential to be used as an interface for further functionalisation with 
molecules that can be of interest for biomedical applications. Their structural similarity to 
CNTs, which also consist of graphene sheets, makes it possible to apply procedures which 
have already been explored for these materials. Two of the most common methods for 
covalent functionalisation of CNTs are the 1,3-dipolar cycloaddition of azomethine ylides 
[104] and the diimide-activated amidation [105], although several other alternatives exist as 
summarised by Hirsch and Vostrowsky [73].  
Diimide-activated amidation is a relatively straightforward method that employs the 
zero-length crosslinker 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) to 
activate carboxylic groups on the surface of CNTs, forming an amine-reactive 
intermediate which subsequently reacts with an amine group to produce a stable amide 
bond [106]. As proteins often have several free amine groups, this is an appealing method 
for the conjugation of such biological molecules to CNTs, which could include targeting 
moieties such as antibodies.  
In the case of FeNS, a similar approach was envisaged, where the first step would be the 
formation of carboxylic functionalities on the graphite shell, after which the procedure 
could then be carried out (Figure 4.1). Acidic treatments have already been shown as an 
efficient way to shorten and generate carboxylic acid functionalities on CNT surfaces by 
oxidation [107] and thus, this approach was also explored for the FeNS. The most 
common method applied for CNTs, which involves their reflux for several hours or days 
in a concentrated solution of nitric and sulphuric acid was however too harsh for the 
FeNS, where pilot experiments resulted in their complete dissolution in the acids.  
 
4 
 Oxidation O
OH
Diimide-activated
amidation O
NH
NH2  
 
Figure 4.1. Functionalisation scheme of FeNS based on diimide-activated amidation. 
Carboxylic functionalities are generated on the surface of the nanoparticles, which are 
subsequently activated by EDC forming an amine reactive intermediate that can react with 
amine containing molecules resulting in the formation of a stable amide bond. 
 
 Thus, a systematic study on the effect of milder acidic treatments was carried out to 
find conditions that would be suitable to generate carboxylic functionalities without loss 
of magnetic properties. Hydrochloric acid, nitric acid or a mixture of nitric and sulfuric 
acid at concentrations of 1 M or 5 M were applied, where the FeNS were immersed in 
those solutions and treated for 15 minutes at 120 oC. After the treatment, the mass 
percentage of nanoparticles left was used as an indication of the amount material leached 
during the treatments. In order to assess if iron was lost during the treatments, the 
magnetic properties of the FeNS were also monitored. As it was shown in chapter 3, the 
saturation magnetisation studied by means of AGM provides a sensitive measure of the 
relative amount of magnetic material in these samples. The results presented in Figure 4.2 
show that a significant amount of material is lost in the acidic treatments and that it 
consists mostly of iron, as reflected by the decay in saturation magnetisation. The results 
indicate that hydrochloric acid results in removal of about 35 % of material, irrespectively 
of the acid concentration, leading to a saturation magnetisation of about 110 Am2/kg. A 
hypothesis for this observation is that the acid dissolved iron particles which could have 
been unevenly coated by graphite, since the same happens with CNTs where HCl is used 
to leach catalyst particles which are not well encapsulated inside the carbon walls. The fact 
that the amount of iron lost in both concentrations is similar is an indication that at 1 M, 
all unevenly coated iron is already dissolved and the reaction does not progress even if 
higher concentrations are used. This is in agreement with a previous study in which 
similar FeNS were treated with 12 M HCl at room temperature for up to 5 h [108]. In 
those studies, about 50 % of iron was lost after 1 h treatment, and no large increase in this 
amount was seen by applying harsher conditions such as higher temperatures or longer 
treatment periods.  
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Figure 4.2. The remaining mass of FeNS and corresponding saturation magnetisation 
after treatments under several acidic conditions. FeNS were treated at 120 oC for 15 
minutes at the indicated conditions, washed and dried. The mass loss corresponds to the 
percentage of dry material after the treatment in respect to the starting amount. 
 
Treatments with nitric acid or a combination of nitric and sulfuric acid, on the other 
hand, resulted in a continuous loss of iron which was proportional to the concentrations 
applied. As it is the case for CNTs, these conditions are more suitable for the generation 
of defects on the carbon shells. At the concentrations applied here, these acid treatments 
probably resulted in extensive damage to the coat of nanoparticles with thinner or more 
structurally defective shells, allowing the dissolution of iron. At the most severe 
conditions (5 M HNO3 and H2SO4) only 10 % of the initial material remained. Those 
probably consisted mostly of partially empty carbon shells, leading to a saturation 
magnetisation of 20 Am2/kg only.  
Samples treated with 1 M HCl and 1 M HNO3 were analysed by XPS in order to assess 
the surface functionalities which were present. Those conditions were selected since they 
provided samples in which the magnetic properties were better preserved. Analysis of C1s 
spectra provides information on functional groups which are present on the graphite coat 
(Figure 4.3a). The dominant peak at a binding energy of 284.63 eV corresponds to the 
graphite structure of the carbon shells. For the sample treated with HNO3, an additional 
peak was observed at 288.75 eV which corresponds to –COO– groups, a condition that 
has been previously observed for CNTs [107, 109]. Fe2p spectra (Figure 4.3b) were 
 similar for all samples, with two peaks at 707 eV and 720 eV separated by doublet splitting 
corresponding to metallic iron and additional shoulders at 711 eV and 724 eV 
corresponding to iron oxide. Those results evidence that the generation of carboxylic 
groups only occurs for particles treated with HNO3 and that iron was still found mostly in 
its metallic state after the treatments, without signs of oxidation under the acidic 
treatments.  
 
         
 
Figure 4.3. Normalised (a) C1s and (b) Fe2p XPS spectra of the raw FeNS powder and 
after treatment with 1 M HCl or 1 M HNO3. 
 
In order to check if the generation of carboxylic groups was facilitated by the generation 
of defect sites on the graphite layers, these samples were also analysed by Raman 
spectroscopy. The results obtained are shown in Figure 4.4, where the previously 
mentioned G (graphite) band and the D (disorder) band are seen at at 1592 cm-1 and 
1295 cm-1 respectively. The ID/IG ratios were calculated as an indication of defect density 
and amounted to 1.15 for the raw material, 1.38 after the HCl treatment and 1.47 after the 
HNO3 treatment, which shows a slight increase according to the conditions applied. As 
the disorder peak can originate from different defects including vacancies, heptagon-
pentagon pairs, kinks and heteroatoms it is difficult to discriminate the direct contribution 
of carboxylic groups from the peak intensity. The defect sites, however, are more sensitive 
to oxidative treatments so that the major contribution of nitric acid could be the 
introduction of carboxylic acid groups on the existing defects rather than the generation 
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of new defects. This is supported by the fact that the increase in ID/IG was not so 
prominent between the HCl and HNO3 treated samples.  
 
 
 
Figure 4.4. Normalised raman spectra of the raw FeNS powder and after  
treatment with 1 M HCl or 1 M HNO3. 
 
4.1.2 Optimisation of the Oxidation Treatments 
 
As only the HNO3 treatments are suitable for the generation of carboxylic groups, an 
optimised procedure was sought where the decay of magnetic properties is not as 
significant as observed at the conditions that were initially applied. For that purpose, a 
second study was conducted where the FeNS were at first treated with 1 M HCl at 120 oC 
for 15 minutes for removal of unevenly coated iron, followed by a subsequent treatment 
with HNO3 at milder conditions for the generation of carboxylic groups. In this case, 
samples were treated with a 5 M concentrated solution of this acid, but at 65 oC for 
progressive periods of time (1 - 5 h). The amount of carboxylic functionalities on the 
FeNS surface was monitored by measuring the decomposition of EDC in the presence of 
particles. The results are presented in Figure 4.5 where it is observed that pure EDC is 
stable without any significant decay in absorbance during the time course of the 
measurement. The same is observed when EDC is exposed to HCl-treated FeNS, a result 
 that is expected since this treatment does not result in the formation of carboxylic 
functionalities (cf. Figure 4.3a). Samples that were additionally treated with HNO3, on the 
other hand, exhibit a time dependent decay resulting from the activation of carboxylic 
groups and consumption of EDC, a clear indication that these functionalities are present 
in the sample. The results show a correlation of decay rate with the time period at which 
the FeNS were exposed to HNO3, implying a larger number of carboxylic groups in the 
samples treated for longer times. The saturation magnetisation was of 101, 98 and 
75 Am2/kg for the FeNS treated with HNO3 for 1 h, 3 h or 5 h respectively, indicating 
that longer treatment periods result in the progressive dissolution of iron. 
 
 
 
Figure 4.5. Time dependent decrease of EDC absorbance at 220 nm during  
exposure to the FeNS at pH 5.5. The treatment applied to each sample is shown in 
parenthesis. 
 
With those results, a standard protocol for the generation of carboxylic groups on the 
FeNS surface was developed, which consisted of an initial treatment with 1 M HCl for 15 
min at 120 oC, followed by an HNO3 treatment for 3 h at 65 oC. This set of conditions 
was chosen based on the fact that it generates a high amount of carboxylic groups (EDC 
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consumption only marginally lower than the longer treatments at 5 h) while the magnetic 
properties are still preserved (saturation magnetisation of 98 Am2/kg, which is only 
slightly lower than the pre-treatment with HCl). FeNS which have undergone this 
treatment are termed FeNS-COOH in the remainder of the text. The respective hysteresis 
loop is shown in Figure 4.6, together with that of the raw material for comparative 
purposes.  
 
 
 
Figure 4.6. Hysteresis loop of FeNS and FeNS-COOH. The inset corresponds to a 
detailed view of the loops at low magnetisation in order to evidence the changes in coercivity 
and remanent magnetisation. 
 
As the focus of these nanoparticles is for thermotherapy applications, the SAR of 
FeNS-COOH was measured and compared with the results previously obtained for the 
FeNS (Figure 4.7). As observed, even after the acidic treatments no decay in heat 
dissipation is seen, even though iron was lost. In fact, a significantly better performance is 
observed, with more energy being released at all magnetic field strengths. The ILP 
reached 0.35 nHm2/kg at 50 kA/m whereas the maximum ILP measured for the FeNS 
was of 0.23 nHm2/kg. Although this effect has not been studied in detail in this work, a 
reasonable hypothesis for these results would be that the acidic treatments changed the 
particle size distribution in the sample (i.e. the acidic treatments selectively dissolved 
particles of a certain size). Several studies involving iron oxides have shown a strong 
dependence of SAR on particle size distribution [50, 110-112], and the acidic treatments 
might have resulted in a optimised size distribution that leads to a higher heat dissipation. 
 An evidence for the changes in size distribution is the decay in coercivity that was 
observed, which went down to 10.8 kA/m from the original 14.4 kA/m of the raw 
material (Figure 4.6, inset). As it was shown in Chapter 1 (cf. Figure 1.6), in the single 
domain range, the coercivity varies with particle size and thus, this could be an indication 
that the average particle size changed with the treatments.  
 
 
 
Figure 4.7. SAR of FeNS and FeNS-COOH as a function of magnetic field strength. 
Values were measured in an aqueous suspension of nanoparticles with a concentration of 
5 mg/ml and at a frequency of 128 kHz. Dashed lines correspond to the quadratic fit of the 
data. 
 
4.2 Functionalisation via Diimide-Activated-Amidation 
 
With adequate conditions for obtaining carboxylic groups on the nanoparticle shell, the 
further functionalisation via diimide-activated amidation is feasible. It is important to note 
that despite the numerous reports on the application of this method to CNTs, a lack of 
controls in those studies has recently been pointed out by Gao and Kyratzis [106]. Their 
major critic is that no publication has effectively shown that the reaction resulted in a 
covalent bond between the CNT and the biomolecule. As most research on the 
functionalisation of CNTs by this method focus on the conjugation of proteins, a limiting 
factor is that even without conditions that lead to a covalent linkage to the CNTs, the 
proteins tend to readily adsorb to the nanotube surface via non-specific interactions, 
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leading to a non-covalent functionalisation [113, 114]. As in many studies techniques such 
as atomic force microscopy, TEM or fluorescence measurements were applied as a 
method to detect proteins on the CNT surface, the possibility that these proteins were 
simply strongly adsorbed rather than covalently bound cannot be discarded.  
To avoid this problem, methylamine (Figure 4.8) was chosen as a model molecule for a 
proof of principle study to show the possibility of covalent conjugation to the FeNS. 
Giving the simple structure of this molecule, strong adsorption would not be expected 
and thus, after the reaction any remaining molecule should be removed in the washing 
steps that follow. For functionalisation, the FeNS-COOH were suspended in 
methylamine and divided in two vessels, to one of which the crosslinker (EDC) was 
added. In this situation, EDC should activate the carboxylic groups of the FeNS-COOH 
that in turn reacts with methylamine leading to the addition of a methyl group to the  
FeNS-COOH surface via an amide link (cf. Figure 4.1). The second vessel was used as a 
control, where the conjugation should not take place but adsorption of methylamine 
would still be possible. After the reaction, the particles were thoroughly washed and 
characterised. 
 
Figure 4.8. Molecular structure of methylamine. 
 
The first step in order to verify whether the reaction was successful was to determine if 
free carboxylic groups were still present in the nanoparticles. For that purpose, the rate of 
consumption of EDC in the presence of these samples was measured (Figure 4.9). The 
stability of EDC when pure or exposed to the FeNS treated with HCl samples is once 
more shown as a reference. The control FeNS-COOH exhibited a time dependent decay, 
an indication that carboxylic functionalities are still present in the sample. When the 
FeNS-COOH are treated with methylamine and the crosslinker, however, the decay is 
much slower, which indicates that part of the carboxylic groups are not present anymore, 
an expected result in the case of a successful conjugation with methylamine. 
 
H
H
H
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Figure 4.9. Time dependent decrease of EDC absorbance at 220 nm during exposure 
to the FeNS at pH 5.5. 
 
Analyses by XPS were carried out in order to confirm this hypothesis. Survey spectra of 
the samples (Figure 4.10) clearly show the peaks corresponding to graphite, metallic iron 
and oxygen in both samples. An additional peak at 399.7 eV corresponding to nitrogen is 
additionally observed for the FeNS-COOH in which the reaction with methylamine and 
EDC was carried out, which agrees with the presence of an amide link. The atomic 
quantification of these spectra (Table 4.1) revealed a 5-fold increase in nitrogen for this 
sample in comparison to the control, which is also reflected in the detailed spectra as 
observed in the inset of Figure 4.10. These results indicate the successful covalent 
conjugation of methylamine to the FeNS-COOH. The control FeNS-COOH does not 
show a significant amount of nitrogen, implying that methylamine adsorption is not 
significant after the several washes that were applied to the nanoparticles.  
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Figure 4.10. Normalised XPS spectra of the FeNS-COOH used for conjugation 
experiments. The control sample was reacted with methylamine only, without the crosslinker 
whereas the conjugated sample was treated with methylamine and the crosslinker (EDC). 
Inset shows the N1s detail spectra. 
 
 
Table 4.1. Atomic concentration (%) of FeNS as calculated from XPS spectra in 
Figure 4.10. 
Sample C1s O1s N1s Fe2p 
FeNS-COOH (control) 83.9 10.8 0.3 5.0 
FeNS-COOH (conjugated) 80.7 12.1 1.7 5.5 
 
 
As surface properties can also affect cellular interactions, the cytotoxicity of the 
modified FeNS were measured and compared with the raw material. The results are 
shown in Figure 4.11 and 4.12 together with the previous results that were obtained for 
the FeNS for comparison. In both cell lines which have been exposed to the 
nanostructures, a slight decay in viability was observed in respect to the raw material, 
especially at the higher concentrations. One possible explanation for these results would 
be that the presence of surface functionalities results in a minor increase in cytotoxicity. 
Similar findings have been observed in the case of CNTs [115] and carbon encapsulated 
nanoparticles [116] that contained carboxylic groups, which would corroborate to this 
hypothesis. In that case, however, it would be expected that the FeNS-COOH conjugated 
 with methylamine would display an intermediate toxicity between the raw material and 
FeNS-COOH, since less carboxylic groups are present after the functionalisation, which is 
not the case. In fact, the decay in metabolic activity is nearly identical in both cases. 
Another possible explanation for this effect concerns the lower density of nanoparticles 
after the acidic treatments. As part of the iron was leached away, the relative amount of 
carbon in the FeNS-COOH is higher resulting in a lower density and thus, a larger 
number of nanoparticles per unit mass. In such a scenario, cells would be exposed to a 
larger number of FeNS-COOH than to FeNS at the same mass concentration, what could 
have an effect in terms of cytotoxicity. How much the surface functionalities, the number 
of particles or a combination of these factors contribute to the decay in metabolic activity 
is however not clear from the results obtained.  
 
 
 
Figure 4.11. Relative viability of DU-145 cells after incubation with FeNS containing 
different surface functionalities. Cells were seeded in 96-well plates, exposed to the 
nanoparticles for 24 h, washed with PBS and incubated with the WST-1 reagent for up to 60 
minutes. Results shown are the mean of measurements performed in quadruplicate and 
normalised to untreated cells. Error bars represent standard deviation and the dashed line 
corresponds to the sigmoidal fit of the data. 
 
 
SURFACE FUNCTIONALISATION OF CARBON ENCAPSULATED NANOSPHERES 
 
57
 
 
Figure 4.12. Relative viability of fibroblasts after incubation with FeNS containing 
different surface functionalities. Cells were seeded in 96-well plates, exposed to the 
nanoparticles for 24 h, washed with PBS and incubated with the WST-1 reagent for up to 60 
minutes. Results shown are the mean of measurements performed in quadruplicate and 
normalised to untreated cells. Error bars represent standard deviation and the dashed line 
corresponds to the sigmoidal fit of the data. 
 
4.3 Fluorescent Labelling of Nanomagnets 
 
With a proof of concept that the conjugation reaction via diimide-activated amidation 
works successfully for this system, the functionalisation with a fluorescent probe was 
carried out. The possibility of having a fluorescent signal from the nanoparticles makes 
their visualisation inside of cells feasible; allowing studies on their cellular uptake as well 
as on their distribution in tissues. The commercial probe used in this study had an 
absorption peak at 623 nm (Figure 4.13) and emission peak at 657 nm according to the 
manufacturer’s data, which corresponds to the red region of the visible spectrum. The dye 
has an additional modification done by the manufacturer to include a terminal amine 
group thus, allowing its covalent coupling to the nanoparticles.  
 
  
 
Figure 4.13. Absorption spectrum of the fluorescent dye used for conjugation with the 
nanoparticles. 
 
The conjugation was carried out as described for methylamine, also including a control 
condition to which EDC was not added. Ultraviolet-visible spectroscopy was applied as a 
method to investigate the realisation of the reaction, where a peak at 623 nm originating 
from the conjugated dye would be expected in the absorption spectrum of the 
nanoparticles. An analysis of the absorption spectra of the powders after the washing 
procedure with distilled water revealed that both samples (control and with EDC) 
exhibited an uneven background, which can be explained as light scattering by the 
suspended nanoparticles, as well as a strong peak at 623 nm (curve 0 in Figures 4.14a and 
4.14b), indicating the presence of the dye in both sets of nanoparticles. A signal from the 
dye would not be expected from the control sample and this effect is likely to have been 
caused by adsorption of the dye to the particles, which were not removed even with the 
washing procedure. This problem, as previously discussed, has been often overlooked in 
functionalisation studies involving CNTs. As most fluorescent dyes (including the one 
used in this work) contain aromatic rings, aromatic stacking with the graphite structure is 
likely to occur, immobilising the fluorophore on the nanoparticle shell. 
These results indicate that further washing steps are necessary in order to remove the 
adsorbed dye. A first attempt to apply additional washes with PBS was not successful. 
Culture medium, which contains phenol red, a dye that also contains aromatic rings was 
hypothesised to have an affinity for graphite and possibly help in the removal of the dye 
but such attempts also failed. As proteins have also shown to have a very strong affinity 
for nanoparticles [117], culture medium containing 10 % fetal calf serum was also used for 
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washing them. Successive washing steps were shown to successfully remove most of 
adsorbed dye, and a progressive decay in its intensity is observed for the control 
condition, as shown in Figure 4.14a. These results suggest that proteins in the culture 
medium have a larger affinity for the nanoparticles than the fluorescent dye thus, leading 
to its progressive desorption. In the conjugated nanoparticles (Figure 4.14b), a significant 
decay in intensity is observed after the first wash and the spectra remains nearly unaltered 
with the subsequent washes. From these results, it can be inferred that most of the 
adsorbed dye was washed away in the first wash and only the covalently bound dye 
remained in the sample. The shift in the absorption peak to a longer wavelength 
(bathocromic shift) after the first wash also supports this hypothesis, as a strong 
interaction with the graphite shell could lead to shifts in the absorbance spectra, as it has 
been also observed for other molecules strongly interacting with carbon nanotubes [118, 
119] and other nanoparticles [120]. The reason why this shift is not observed before the 
first wash can be attributed to the high amount of adsorbed dye at this condition, masking 
the peak of the covalently bound ones. These observations highlight the need of 
appropriate washing steps after conjugation procedures that completely eliminate any 
molecules which are still adsorbed to the nanoparticles. 
 
       
 
Figure 4.14. Absorption spectra of the nanoparticles after conjugation with the 
fluorescent dye. (a) corresponds to the control conditions to which no crosslinker was added 
and (b) to the conjugated condition. The numbers indicate the number of times they were 
washed with completed medium. The spectra are stacked for better visibility and as a 
consequence, baselines do not coincide.  
 
 4.4 Fluorescent Imaging of Nanomagnets in Cells 
 
Given their reduced dimensions, nanoparticles have been often investigated as a carrier 
for therapeutic molecules. Besides taking advantage of passive drug delivery systems such 
as the enhanced permeability and retention seen for tumour tissues, small particles are 
easily taken up by cells thus, facilitating the delivery of therapeutic molecules directly to 
the intracellular space [121]. Given their carboxylic functionalities, the FeNS-COOH 
could be additionally explored as a carrier for drugs or other molecules of therapeutic 
interest that could be conjugated to the nanoparticles via its surface functionalities. The 
use of FeNS-COOH as carrier for drugs will be discussed in detail in the next chapter. 
Here, the fluorescent functionalisation is applied as a tool to show nanoparticle 
internalisation by cells thus, showing the feasibility of using these structures for the 
delivery of molecules of interest. When hyperthermia is considered, the direct delivery of 
the nanoparticles to the intracellular space is not of great relevance since it is unlikely that 
the therapeutic efficacy of the therapy is influenced by the source of heat (intracellular or 
extracellular space), as long as an increase of temperature is obtained [122]. 
In line with the biocompatibility studies, fibroblasts and DU-145 cells were used as 
model systems which were exposed to a fixed concentration of the nanoparticles 
(50 µg/ml) for 24 h to allow their uptake. After this period, cells were prepared for 
confocal imaging where additional staining was applied to the cytoskeleton (actin 
filaments) and to the nuclei.  
From the results presented in the previous section, it is not possible to completely 
exclude that some of the fluorescent dye stays adsorbed after the conjugation reaction. 
That would mean that once in cell culture, the dye could desorb and be taken up by cells 
as a free molecule giving false positive results, where the signal of the free dye could be 
obtained instead of the dye conjugated to the nanoparticles. 
For this reason, control experiments were carried out to observe if the free dye is taken 
up by cells. The two cells lines were incubated with the free dye diluted in the culture 
medium at a concentration of 10 µg/ml as well as with the two set of nanoparticles 
obtained in the previous experiments, including the control condition to which the dye 
was only allowed to adsorb to the nanoparticles. In both cases, the nanoparticles were 
washed at least 5 times with culture medium to minimise the amount of adsorbed dye.  
In Figure 4.15, the results obtained for cells incubated with the dye only are shown. 
Clear signals are obtained from the nuclei and actin staining, but no fluorescent was 
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detected in the red region, indicating that the free dye is not taken up by cells. Similar 
results are obtained when cells were exposed for 24 h to the nanoparticles that were 
reacted with the dye, but without the crosslinker, where no signal was obtained in the red 
region (Figure 4.16). This indicates that if nanoparticles are taken up by the cells, this 
process only happens for the ones from which the dye has desorbed. Cells exposed to the 
nanoparticles reacted with the fluorescent dye and the crosslinker, on the other hand 
display a clear red fluorescent signal originating from the intracellular space (Figure 4.17), 
showing that the dye was internalised by cells. As the control conditions involving the free 
dye only did not show its uptake, it is possible to imply that the red fluorescence 
corresponds to a fluorescent probe which is covalently attached to the nanoparticles. 
  
 
 
 
 
 
Figure 4.15. Confocal microscopy images of DU-145 cells (top) and fibroblasts 
(bottom) after 24 h incubation with a red fluorescent dye. Green fluorescence 
corresponds to actin (phalloidin staining) and the blue fluorescence to the nuclei (DAPI 
staining). 
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Figure 4.16. Confocal microscopy images of DU-145 cells (top) and fibroblasts 
(bottom) after 24 h incubation to the control FeNS-COOH containing adsorbed red 
fluorescent dye. Green fluorescence corresponds to actin (phalloidin staining) and the blue 
fluorescence to the nuclei (DAPI staining). 
  
 
 
 
 
 
Figure 4.17. Confocal microscopy images of DU-145 cells (top) and fibroblasts 
(bottom) after 24 h incubation to the FeNS-COOH conjugated to a red fluorescent 
dye. Green fluorescence corresponds to actin (phalloidin staining) and the blue fluorescence 
to the nuclei (DAPI staining). 
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 DRUG CONJUGATION: FEASIBILITY AND IN VITRO 
EFFECTS IN COMBINATION WITH HYPERTHERMIA 
 
5.1 Exploring Carboxylic Functionalities for Drug Conjugation 
 
Beyond the conjugation of biological molecules via amidation reactions, carboxylic 
functionalities can also be exploited for conjugation with drugs. A successful example is 
the conjugation of the anticancer compound cisplatin to polymers [123-125]. In these 
studies, the chloro ligands of the drug are replaced by carboxylic acid terminations of 
polymers (Figure 5.1) linking the drug directly to the polymer and thus, allowing the 
realisation of a polymeric carrier for drug delivery. 
 
 
Figure 5.1. Schematic representation of the complexation mechanism of cisplatin and 
carboxyl groups from acrylic acids as proposed by Yan and Gemeinhart [125]. 
 
 From these studies, it is possible to hypothesise that such methods would also allow the 
conjugation of cisplatin to the FeNS-COOH. In such a scenario, these particles could not 
only be used for MFH but also for bi-modal treatments involving hyperthermia and 
chemotherapy. As it was discussed in section 1.1.2, heat is a great enhancer of 
chemotherapy and in the case of cisplatin, it has been shown to help overcome the effect 
of chemoresistance that is often developed by malignant cells [126]. 
Cisplatin is a platinum complex which is bound to two chloride and two ammine ligands 
via weak coordination bonds. In aqueous solutions, a ligand exchange process takes place 
in which the chloride ligands are replaced by water converting the drug to a very reactive 
aquated form. This happens in two steps as shown in Figure 5.2, resulting in mono and 
diaquated cisplatin, respectively [127]. 
5 
  
Figure 5.2. Aquation of cisplatin to the cationic monoaqua and to the dicationic 
diaqua species. Image reproduced from reference [127].  
 
In aqueous solutions, the exchange reaction does not proceed to completion and 
equilibrium exists between the chlorinated form and the aquated forms of the drug. One 
method to increase the efficiency of the exchange reaction is to abstract the chloride ions 
from the solution, displacing the reaction in the direction of the formation of the aquated 
form. For that purpose, cisplatin was at first reacted with silver nitrate (AgNO3) as 
suggested in previous studies [128]. In this reaction, Ag+ reacts with Cl- forming the non-
soluble silver chloride (AgCl) and depleting the solution of Cl-. As a result, the reaction is 
displaced to the formation of the diaquated form of the drug. A centrifugation step was 
used to concentrate the AgCl and the supernatant (diaquated cisplatin) was then reacted 
with the nanoparticles. This reaction leads to a complex where the water molecules are 
replaced by the carboxyl groups in the nanoparticle. 
In order to illustrate the role of the carboxylic functionalities on the amount of drug 
loaded onto the nanoparticles, two different routes were applied for cisplatin 
complexation. In the first route, FeNS-COOH were directly reacted with cisplatin 
whereas in the second route, FeNS-COOH were firstly conjugated with methylamine and 
then reacted with cisplatin. The rationale of the second route was to consume part of the 
carboxylic functionalities on the nanoparticle surface by reacting them with methylamine. 
In that case, a lower drug loading is expected since less carboxylic functionalities are 
available for reacting with cisplatin. The two loading routes are illustrated in Figure 5.3 
and the resulting nanoparticles were termed FeNS-CDDP and FeNS-MA-CDDP as 
illustrated.  
The complexation reaction was carried out overnight, followed by studies on the 
cisplatin release from the particles. For that purpose, the loaded FeNS were incubated 
with water or saline solutions for up to 26 days and supernatant samples were taken 
periodically for cisplatin measurement. The results shown in Figure 5.4 display a time 
dependent drug release which is only expressive in saline solutions for either of the 
loading routes. These results are in agreement with the previous discussion considering 
the ligand exchanges. In the presence of water only, the drug-nanoparticle complex is 
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stable and no release is observed. When incubated with saline, on the other hand, the 
chloride ions replace the carboxylic groups to which the drug is bound, bringing it to its 
original form. Those results are also in agreement with previous studies involving cisplatin 
bound to polymers via ligand exchange, where the drug release was also higher in saline 
[123].  
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Figure 5.3. Schematic representation of the two drug loading routes. In the first one, the 
FeNS-COOH are directly reacted with cisplatin. In the second route, an intermediate step was 
applied were the FeNS-COOH were conjugated to methylamine prior to the reaction with 
cisplatin.  
 
Of the total drug released during the 26 days, nearly 50 % of it is released in the first 
24 h, whereas the remainder is slowly released in the following days. The total amount of 
drug released from the FeNS-CDDP was of 12.8 µg/mg whereas for FeNS-MA-CDDP it 
was of 5.8 µg/mg. The dependence of total drug loaded on the amount of free carboxylic 
groups on the nanoparticles is evidence that the complexation via ligand exchange is likely 
to be the main mechanism for drug loading, rather than simply adsorption. The 
confirmation that FeNS-MA-CDDP also contained cisplatin in significant amounts opens 
up the possibility for multifunctionalised nanoparticles where instead of the model 
molecule, methylamine, other molecules of relevance could be attached. Those could 
include for example, targeting antibodies or molecules that might improve the 
biocompatibility of the nanoparticles.  
Given the potential application for hyperthermia, the influence of temperature on drug 
release was also investigated. For those studies, the nanoparticles carrying the highest 
amount of drug (FeNS-CDDP) were used as a model. Freshly prepared FeNS-CDDP 
were incubated for 30 minutes at four different temperatures and the amount of drug 
 released was measured. This time period was chosen in view of clinical hyperthermia 
treatments which are often carried out for periods of 30 to 60 minutes. 
 
 
 
Figure 5.4. Time dependent cumulative drug release from FeNS-CDDP and FeNS-
MA-CDDP. The nanoparticles were suspended in water or saline and at different time 
points, the nanoparticles were concentrated at the bottom of the tube with a magnet and the 
supernatant removed for platinum measurement. Immediately after removal of the 
supernatant the nanoparticles were resuspended in fresh solution. The curves show the mean 
cumulative release of CDDP ± SD from three independent experiments. The values in the 
ordinate correspond to the amount of drug released per milligram of nanoparticle. 
 
The results shown in Figure 5.5 show a temperature dependent release where at 4 oC, 
less than 0.2 µg/mg of cisplatin was released. At body temperature (37 oC), 0.84 µg/mg 
was released and this value was nearly doubled (1.43 µg/mg) when hyperthermia 
temperatures were applied (43 oC). The amount of drug released reached 2.20 µg/mg at 
thermoablative conditions (50 oC). Those results are of interest in light of the synergistic 
effect of heat and drugs when they are applied together. In that case, a burst release of 
drug would be feasible with heating thus increasing the drug concentration at the tumour 
site at the same time at which hyperthermia is applied. 
In order to be effective in an anti-cancer therapy, the drug in question must be still 
active after the loading and release processes. For that purpose, the cytoxicity of 
FeNS-CDDP was compared to that of FeNS-COOH by measuring the metabolic activity 
of the prostate cancer cell line DU-145 after 72 h exposure. This incubation period was 
DRUG CONJUGATION  
 
69
chosen in order to give time to the drug to have an effect on the cells. As cisplatin works 
by interfering with cell division, incubation periods longer than 24 h are more effective in 
showing its effects. Figure 5.6 shows the decay in metabolic activity after exposure to 
different nanoparticle concentrations ranging from 1-1000 µg/ml. A comparison of the 
two curves clearly shows that the FeNS-CDDP is shifted to lower concentrations, 
indicating an increase in cytotoxicity. The calculated IC50 values amount to 359 µg/ml and 
86 µg/ml for the FeNS-COOH and FeNS-CDDP respectively, implying a 4-fold decrease 
for the cisplatin loaded nanoparticles.  
 
 
 
Figure 5.5. Temperature dependent drug release from FeNS-CDDP. Freshly prepared 
nanoparticles were suspended in saline and immediately incubated at 4 oC, 37 oC, 43 oC or 
50 oC for 30 minutes. After this period, nanoparticles were concentrated at the bottom of the 
tube with a magnet and the supernatant was taken for cisplatin measurement. The graph 
shows the mean release of CDDP ± SD from three independent experiments. The values in 
the ordinate correspond to the amount of drug released per milligram of nanoparticle. 
 
The drug release curves (Figure 5.4) indicate that after 72 h in saline, the amount of 
cisplatin released is 9 µg per milligram of FeNS-CDDP. That means that at its IC50 value 
(86 µg/ml) a cisplatin concentration of about 0.75 µg/ml would be expected. This is in 
good agreement with the reported IC50 values of cisplatin alone for this cell line, which is 
0.5 µg/ml after a 72 h treatment [129]. It can thus be reasoned that the observed 
cytotoxicity derives from the drug. Cisplatin acts by crosslinking DNA strands, interfering 
with mitosis and inducing apoptosis. When the pure drug is considered, the crosslinking 
 process is triggered upon cellular uptake, where the lower chloride content of the 
cytoplasm leads to aquation of the molecule which, given its high activity, interacts with 
the DNA bases generating crosslinks [130]. These results show that after being released 
from the nanoparticles, the drug is still active and able to undergo these processes and 
induce cell death. 
 
 
 
Figure 5.6. Relative viability of DU-145 cells after incubation with FeNS-COOH or 
FeNS-CDDP at different concentrations. Cells were seeded in 96-well plates, exposed to 
the nanoparticles for 72 h, washed with PBS and incubated with the WST-1 reagent for up to 
60 minutes. Results shown are the mean of measurements performed in quadruplicate and 
normalised to untreated cells. Error bars represent standard deviation and the dashed line 
corresponds to the sigmoidal fit of the data. 
 
Cells incubated with FeNS-COOH also displayed a significant decay in metabolic 
activity. As previously observed, this was more prominent at the highest concentrations 
and more significant than the effects seen in chapter 3 (cf. Figure 4.10). It is important to 
note, however, that an incubation period of 72 h was applied here and not just 24 h as 
previously. Besides the increased exposure time, this time period also allows a partial 
sedimentation of the nanoparticles over the cells, even with the use of methylcellulose. 
Thus, the increase in cytotoxicity could be a response to sedimentation of nanoparticles 
interfering with cell proliferation and not necessarily an increase in the intrinsic toxicity of 
the particles. 
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5.2 In vitro Effects of Thermotherapy using Drug Loaded Iron 
Nanoparticles 
 
The in vitro efficacy of thermotherapy using FeNS-COOH or a combination of 
thermotherapy and chemotherapy using FeNS-CDDP was studied by exposing DU-145 
cells to either type of nanoparticles for 30 minutes at different temperatures (37 oC, 43 oC 
or 48 oC). Cells and nanoparticles were suspended together in culture medium containing 
methylcellulose and then exposed to an alternating magnetic field in order to reach the 
hyperthermic or thermoablative temperatures. The temperature profile of a typical 
experiment is shown in Figure 5.7 where the temperatures achieved were of 42.5 ±0.3 oC 
and 47.5 ±0.4 oC for hyperthermia and thermoablation conditions, respectively. 
 
 
 
Figure 5.7. Temperature evolution of cell suspensions in cell culture medium  
containing the iron nanospheres. Heating was achieved with a magnetic field of  
60 kA/m and frequency of 128 kHz. Temperature readings were taken every 1 s with a fiber 
optic temperature sensor.  
 
After heating, 130 cells were taken from the solution and seeded in order to investigate 
their clonogenic survival. The results show that treating cells with FeNS-COOH at 37 oC 
results in a 29 % decay in the number of colonies which is not statistically significant 
(Figure 5.8). The hyperthermia treatment (43 oC), on the other hand, led to a significant 
decay in the number of colonies formed, which is down to 33 % in relation to untreated 
 cells. A complete induction of cell death at those conditions is not expected for two 
reasons: at first hyperthermia was induced in a single session of 30 minutes only. 
Secondly, the physiological conditions which makes tumours more sensitive to 
temperatures (such as low pH and hypoxia) were not present in these in vitro conditions, 
where cells were evenly exposed to a balanced pH, oxygen tension and nutrients and thus, 
a large hyperthermia sensitivity is not expected. A temperature of 43 oC is thus not 
enough to have a complete cytotoxic effect under the conditions that were applied. At the 
thermoablative temperatures (~ 48 oC), however, death by necrosis is expected, which is 
reflected in the results where no cells were able to form colonies.  
 
 
 
Figure 5.8. Colony formation by cells subjected to different thermotherapy treatments 
with FeNS-COOH or FeNS-CDDP. Results are normalised to control (untreated) 
conditions. A total of 2×104 cells were treated for 30 minutes with a 5 mg/ml solution of 
nanoparticles suspended in culture medium. Heating was achieved under an AC magnetic 
field with H = 60 kA/m at f = 128 kHz . After the treatment, 130 cells were plated in each 
well of 6-well plates. Following 8 days of culture the colonies were stained and counted. 
Results shown are the mean of three replications and error bars represent standard deviation. 
Asterisk (*) denotes statistical difference in relation to the control group (p < 0.05). 
 
Cells exposed to the drug loaded nanoparticles (FeNS-CDDP) did not form any 
colonies in any of the treatment groups. The studies on the temperature dependent release 
have shown that 30 minutes at 37 oC is enough to have a release of about 
0.85 µgCDDP/mgnanoparticle (cf. Figure 5.5). That would mean that a 5 mg/ml solution of 
FeNS-CDDP as it was applied here would lead to cisplatin concentrations higher than 
DRUG CONJUGATION  
 
73
4 µg/ml at this temperature. This value is 8-fold above the IC50 observed for 72 h 
exposure [129]. Although the exposure in this experiment was relatively short (30 min), 
the results clearly show that at this high drug concentrations death is induced in all cells.  
 
5.3 Relationship between in vitro studies and Clinical Conditions  
 
Even though the amount of drug released in these in vitro conditions was so high that all 
cells were killed even with a short incubation period at 37 oC, one should not consider 
that the drug loading in the nanoparticles is excessive. In fact, the situation in an in vivo 
setting would certainly be different and most likely; the concentrations achieved here 
would be too low for an effective treatment. Depending on the clinical situation, cisplatin 
dosage for systemic treatments in vivo can be as high as 34-200 mg per day for a patient of 
average height and weight [131], with such limits often imposed by systemic toxicity and 
adverse side-effects. Although the drug concentrations that are achieved at the malignant 
cells are effectively lower given the quick clearance of the drug as well as the limited 
tumour outreach, they are probably still much higher than the ones to which cells were 
exposed in these experiments (maximum of 10 µg/ml for cells treated at thermoablative 
conditions). 
It must be considered that in the in vitro condition, several features of an in vivo tumour 
are lacking, a situation that will be discussed in the next chapter, which makes the cells 
more sensitive to the drug treatment. Additionally, the conditions achieved in vitro are very 
favourable in terms that all cells are cultured in a uniform environment and evenly 
exposed to the drugs. If one considers the nanoparticle concentration of magnetic fluids 
which are used in clinical studies, which are on the order to 100 mg/ml [42, 43], the drug 
concentrations that could be achieved would be much higher. At this particular 
concentration and under ideal conditions the local amount of cisplatin release after 24h 
could reach 650 µg per millilitre of magnetic fluid instilled, according to the results plotted 
in Figure 5.4. Such ammounts would likely have a significant cytotoxic effect that could be 
further augmented by the concomitant application of hyperthermia. 
It is also important to bring into discussion that the magnetic fields that were applied 
(60 kA/m) would probably be too high for application in clinical practice. As it was 
discussed in the first chapter, limiting fields are on the order of 15 kA/m in humans to 
avoid local discomfort. Here, high magnetic field amplitudes were applied to account for 
 the relatively low concentration of nanoparticles, which was of 5 mg/ml. It can be 
considered, however, that that if concentrations similar to those which are used in clinical 
studies (100 mg/ml) would be applied, satisfactory heating could be achieved at lower 
fields.  
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 APPLICATION TO THREE-DIMENSIONAL TUMOUR 
MODELS 
 
 
6.1 Establishment of Multicellular Tumour Spheroids 
 
In the first chapters of this work, the feasibility of using FeNS for thermotherapy and 
the potential surface functionalities have been explored. Although several in vitro studies 
were performed to screen their cytotoxicity as well as the effects of thermotherapy, those 
involved the culture of cells as monolayers or suspensions. Despite the fact that these are 
the most common methods for cell culture in vitro, it is recognised that they lack several 
features which are found in vivo. Characteristics such as a three-dimensional organisation, 
cell-cell interactions, presence of an extracellular matrix and the existence of nutrient and 
oxygen gradients do not exist when cells are grown as monolayers. These differences 
between in vitro monolayer/suspension cultures and in vivo tumours are so important that 
it has been hypothesised that they could be the reason for the difficulty of translating 
in vitro responses of radio- and chemotherapy to in vivo tumours [132]. 
As early as in the seventies, the use of more organised in vitro structures denominated 
“multicellular tumour spheroids” (MTS) were proposed by Sutherland, et al. [133]. Such 
MTS can be considered as intermediate models between monolayer cultures and in vivo 
tumours [134] and consist of three dimensional clusters of cells in the form of a sphere, a 
condition that can be obtained for several types of cells when their attachment to a 
substrate is prevented. Some of their features include cell-cell and cell-matrix interactions, 
a spatial geometry that produces defined drug and nutrient concentration gradients and 
subpopulations of cells which are quiescent, hypoxic, necrotic or near-necrotic [134-136] 
thus, being a more realistic model of a tissue. 
Several methods have been described for the culture of spheroids as summarised by 
Friedrich, et al. [136]. In this work, a technique originally employed for the culture of 
endothelial cells was applied, where single spheroids are obtained in 96-well plates [137]. 
This method has the advantage that all spheroids are formed from a definite number of 
cells, having similar sizes and thus, displaying a better reproducibility. Additionally, 
individual spheroids are conveniently obtained in multiwell plates.  
6 
 The period necessary for cells to aggregate and form an spheroid varies according to the 
cell line and it can range from a few hours up to a few days. In the case of DU-145 cells, a 
compact mass of cells is obtained after four days (Figure 6.1) but their diameter decreases 
for up to 14 days corresponding to a greater densification (Figure 6.2). After this period, 
the spheroids grow linearly with time.  
 
 
 
Figure 6.1. Images of cells seeded in U-bottom 96-well plates at different time points. 
The cell agglomeration and the formation of a spheroid is observed. Cells were seeded in 
culture medium containing methylcellulose which avoids their attachment to the surface. 
 
 
 
Figure 6.2. Growth curve of DU-145 spheroids during 42 days of culture. Micrographs 
were obtained at each time point, from which two orthogonal measurements of diameter were 
taken for volume calculation. Results shown are the mean of 5 spheroids (each consisting of 
5×103 cells) and error bars represent standard deviation. 
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Electron microscopy techniques can be applied for analysing the shape and outer 
morphology of the spheroids. For the cell line in question, their round shape and the 
individual cells can be easily identified (Figure 6.3). For other cell lines, however, the 
surface can be much smoother, to a level in which the individual cells are not identified. 
In certain cases, the presence of an extracellular matrix can also be observed [132].  
 
   
 
Figure 6.3. Images of a spheroid after 16 days of culture as obtained by SEM. The 
image on the left shows the full spheroid and the image on the right shows details of its 
surface as obtained at a higher magnification. The spheroid was fixed, dehydrated and 
sputtered with gold to allow imaging under a standard scanning electron microscope. 
 
Another clear difference between monolayer culture and spheroids corresponds to their 
cell cycle. Whereas monolayer culture of cancer lines commonly exhibit cells in a highly 
proliferative state, cells in spheroids are much less proliferative, being normally restricted 
to cells located at their surface [132]. This characteristic is also true for DU-145 spheroids 
as shown in Figure 6.4. Most of the cells are found at the G0/G1 phase which is in good 
accordance to the situation found in adult tissues, whereas in monolayer culture, a higher 
fraction of cells are found in the S phase. Histological analysis of the spheroids also 
reveals a tissue like structure, as shown in Figure 6.4. 
 
      
 
Figure 6.4. Cell cycle distribution of DU-145 cells grown as monolayers or spheroids. 
The cell cycle results correspond to spheroids consisting of 5×103 cells. In the right panel a 
tissue section of the respective spheroids is shown, where its resemblance to an in vivo tissue is 
observed. Spheroids were stained with haematoxylin and eosin. 
 
As observed from the SEM and histology images, nutrients, oxygen and metabolites 
must diffuse through the spheroid in order to reach the cells which are found in its core, 
which leads to concentration gradients. The same happens to catabolites which are 
generated in the center of the spheroid and which are not easily cleared from this region. 
These features are in strong contrast with cells grown as monolayers, in which the culture 
medium (and consequently the nutrients and oxygen) are evenly distributed among all 
cells. When compared to a tumour, or a micrometastasis, a similar situation is found given 
their chaotic vasculature. As it was discussed in chapter 1, their irregular and abnormal 
microvasculature also leads to inhomogeneities in nutrients and oxygen. The similarities 
between multicellular tumour spheroids and an in vivo tumour are highlighted in 
Figure 6.5. It is important to note that for spheroids of large diameters, the lack of 
nutrients and oxygen at its center, together with the increased pH due to the accumulation 
of catabolic products might lead to a necrotic core. The spheroids used in this work did 
not show this characteristic, a condition that is likely due to their relatively small 
diameters.  
As a consequence of these differences, spheroids are often more resistant to drugs than 
cells grown as monolayers [138-140]. These differences can arise because of reduced 
exposure to the drug, which has to penetrate the spheroid in order to reach the cells at the 
core or because of cell cycle differences. The later can be especially true for cisplatin, 
which has its cytotoxic effect based on DNA damage and cell replication. Therefore, the 
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quiescent cells in the centre of the spheroids are less sensitive to the effects of the drug. 
In fact, this behaviour has been demonstrated in hamster V79 spheroids, in which the 
cisplatin resistance was measured for different fractions of the spheroids [141]. In this 
study, the authors have shown that cells in the rim of the spheroids are more sensitive to 
cisplatin than those at the core.  
 
 
Figure 6.5. Microenvironmetal similarities between multicellular tumour spheroids 
and an in vivo tumour. At distances far from the medium or capillary the concentration of 
oxygen, metabolites and nutrients is lower, whereas the accumulation of catabolites is higher. 
Cell proliferation also varies accordingly. Image reproduced from reference [136]. 
 
The cisplatin sensivity of DU-145 cells grown as monolayers or spheroids is shown in 
Figure 6.6. A difference of nearly 5-fold in the toxicity of the drug is observed for a 
continuous 72 h exposure, with IC50 values of 0.5 µg/ml for the cells grown as 
monolayers or 2.4 µg/ml for cells grown as spheroids. Their higher resistance is an 
advantage in this study, since it makes them more adequate as a model for the effects of 
the FeNS-CDDP developed in chapter 5. At first, because of their similarities to in vivo 
tumours that makes them more suitable for in vitro testing. Second, because the higher 
drug resistance facilitates observing a synergistic effect of the combination of drug and 
hyperthermia, which was not possible with the individual cells. As cells grown in 
monolayer or suspension culture are too sensitive to the drugs, the simple exposure to the 
FeNS-CDDP was enough to result in complete cell death given the high amount of drug 
loaded in the particles (cf. Figure 5.8).  
 
  
 
Figure 6.6. Relative viability of DU-145 cells grown as monolayers or spheroids after 
72 h exposure to different concentrations of cisplatin. Cells or spheroids were grown in 
96-well plates, exposed to the drug for 72 h, washed with PBS and incubated with the WST-1 
reagent for up to 60 minutes (5 h for spheroids). Results shown are the mean of 
measurements performed in quadruplicate (8 replications for spheroids) and normalised to 
untreated cells. Error bars represent standard deviation and the dashed line corresponds to 
the sigmoidal fit of the data. Spheroids were obtained from 10×103 cells. 
 
 
6.2 Effects of Thermotherapy on the Metabolic Activity of Spheroids 
 
As a first step towards using MTS for thermotherapy studies, the time dependent 
changes in metabolic activity of spheroids following a single 30 minute exposure to 
different temperatures was evaluated. For that purpose, heating was achieved simply by 
incubating a micro test tube containing the spheroids in a water bath. The results shown 
in Figure 6.7 reveal that heat is well tolerated up to temperatures of 44 oC. At 
temperatures of 46 oC, 48 oC and 50 oC, a clear decay in viability with time is observed. 
The use of the absolute temperature as a reference for cytotoxicity is however not 
optimal, for the reasons discussed in chapter 1. For comparing treatments, the 
corresponding cumulative equivalent minutes at 43 oC (CEM(43 oC)) is more appropriate 
as a parameter and therefore, these values are also shown in Figure 6.7. When the 
CEM(43 oC) is considered, a value higher than 60 seems to be critical in order to induce a 
cytotoxic effect. A similar study conducted by Samideh et al. [142], that also investigated 
the effects of hyperthermia on DU-145 spheroids, has shown that they have a relatively 
high temperature resistance. The longest CEM(43 oC) applied in their study was 120, at 
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which the majority of the cells in the spheroid could still form clonogenic colonies (more 
than 60 %). In another study involving BT4C rat glioma spheroids, no effects were seen 
for CEM(43 oC) lower than 120 either. These results are in good agreement with the data 
shown here, in which a long term cytotoxic effect was only seem at a CEM(43 oC) of 240 
or higher. 
 
 
 
Figure 6.7. Relative viability of DU-145 spheroids (obtained from 10×103 cells) after a 
30 minute thermotherapy session in a water bath. Spheroids were pooled together in 
micro test tubes, treated in a water bath and transferred back to 96-well plates containing an 
agarose coat. After 24 h, 48 h or 72 h the spheroids were incubated with the WST-1 reagent 
for up to 5 h. Results shown are the mean of 8 replications and normalised to untreated cells. 
Error bars represent standard deviation. Spheroids were obtained from 10×103 cells. 
 
These findings demonstrate that at hyperthermic temperatures (42-43 oC), longer 
treatment periods are necessary in order to see significant cytotoxic effects. Alternatively, 
short periods at thermoablative temperatures are sufficient, as a clear decay in metabolic 
activity is observed at 46 oC, 48 oC and 50 oC. The later two conditions lead to extremely 
high CEM(43 oC), resulting in complete death of the spheroids. 
 6.3 Effects of Thermotherapy Induced with Nanomagnets  
 
Thermotherapy was also induced with the nanomagnets. The conditions applied were 
the same as for the cell suspensions presented in chapter 5. More specifically, the studies 
involved treatments at 43 oC and 48 oC for a period of 30 minutes using FeNS-COOH or 
FeNS-CDDP. Studies with the FeNS-COOH resulted in a small decay in viability, with 
the lowest value being 68 % for the spheroids treated at 48 oC (Figure 6.8). When 
compared with the results obtained by heating the spheroids with a water bath only 
(Figure 6.7), a stronger effect would be expected at this temperature. In the water bath 
experiments, viability after 72 h was less than 20 % whereas when heated with the FeNS-
COOH, viability was still as high as 64 %. As such thermoablative temperatures result in 
irreversible cell damage, it is unlikely that some mechanism of protection was present in 
the treatments with the FeNS-COOH. A hypothesis for this effect is that the 
temperatures achieved in the spheroids were not as high as the values that were measured 
during the experiments. Such a situation could happen given the fact that the spheroids 
sediment to the bottom of the tube during thermotherapy because of their high mass. As 
a consequence, the spheroids find themselves in contact with the tube walls. As the tube 
walls are the area of heat exchange with its surroundings, it is reasonable to assume that 
the temperatures near the walls are slightly lower than the average temperature that was 
measured for the solution, explaining the reduced cytotoxic effect under these conditions. 
This situation is schematically illustrated in Figure 6.9. This hypothesis would also account 
for the successful application of thermoablation to the cell suspensions discussed in 
chapter 5. As individual cells are much lighter, they stay suspended during the course of 
the experiment and consequently, in thermal equilibrium with the surrounding fluid.   
Even when slight differences in temperature are accounted for, a cytotoxic effect 
proportional to the temperature dose is observed for the cells that underwent 
thermotherapy. When FeNS-CDDP were used for achieving hyperthermia conditions, an 
increased decay in cell viability was observed, demonstrating the stronger effect of the 
combined treatment with cisplatin, which is in accordance with similar studies involving 
spheroids [143, 144]. As it was discussed in the previous chapter, a FeNS-CDDP solution 
with a concentration of 5 mg/ml leads to a cisplatin concentration of about 7 µg/ml 
during the hyperthermic treatment. It is important to note, however, that the cytotoxic 
effect of this concentration cannot be directly compared with the results shown in Figure 
6.6, from which IC50 values were obtained. In that case, the exposure to the drug was 
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72 h, whereas here, the exposure was only during the 30 minutes of thermotherapy as the 
spheroids were washed before being further incubated in 96-well plates. Thus, a smaller 
effect must be expected from the drug. Such condition is however more realistic when 
clinical conditions are considered. When applied in vivo, cisplatin is quickly cleared from 
the body. After an injection, for example, the drug concentration in the plasma decays 
very quickly, with an elimination half-life as short as 43 minutes [131].  
 
 
 
Figure 6.8. Relative viability of spheroids (obtained from 10×103 cells) subjected to 
different thermotherapy treatments with FeNS-COOH or FeNS-CDDP. Results are 
normalised to control (untreated) conditions. A total of 8 spheroids were treated for 30 
minutes with a 5 mg/ml solution of nanoparticles suspended in culture medium. Heating was 
achieved under an AC magnetic field with H = 60 kA/m at f = 128 kHz. After the treatment, 
the spheroids were grown for further 72 h in 96-well plates. After this period, WST-1 agent 
was added to the spheroids followed by an incubation period of up to 5 h. Results shown are 
the mean of 8 replications and error bars represent standard deviation. Spheroids were 
obtained from 10×103 cells. 
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Figure 6.9. Experimental arrangement of cells and spheroids during thermotherapy 
studies. Individual cells stay suspended in the fluid reaching thermal equilibrium. Cell 
aggregates (spheroids), on the other hand, sediment at the bottom of the tube and exchange 
heat with the tube wall. RT stands for room temperature. 
 
Spheroids treated with the nanoparticles were additionally grown for a period of up to 
24 days after thermotherapy during which their volume was observed. The growth rate is 
an additional indicator of spheroid viability, and an important parameter to investigate the 
long term effects of hyperthermia with or without the combination of drugs. The results 
obtained are shown in Figure 6.10. Untreated spheroids display a slow but linear increase 
in volume during the time course of the experiment. Conversely, spheroids treated with  
FeNS-COOH exhibit an initial decay in volume which is then followed by an accentuated 
growth rate. Spheroids that were treated with the nanoparticles only, without heating, 
displayed a quick recovery in volume until it reached the same size as untreated cells, after 
which it followed a steady growth. Cells treated at 43 oC or 48 oC presented a slower rate 
of recovery but also had a tendency to regrow and after the period of 24 days, their 
average volume was the same as untreated spheroids. Although the reason for an initial 
decay in volume is not clear from those experiments, it is possible to infer that 
thermotherapy does have an influence on spheroid growth, which is also supported by the 
viability measurements. It is possible to speculate that if a longer CEM(43 oC) would be 
administered or, if more hyperthermia sessions would be applied, the growth of the 
spheroids could be arrested. A subsequent thermotherapy session could be applied after a 
period of 3 or 5 days, for example, where thermoresistance would likely have been 
overcame. Such conditions could possibly inhibit the recovery in spheroid size.  
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Figure 6.10. Spheroid growth after thermotherapy treatments. After heating, spheroids 
were throughly washed to remove excess drug and nanoparticles and then allowed to grow 
individually in 96-well plates with weekly culture medium changes. Micrographs were obtained 
at each time point, from which the two orthogonal measurements of diameter were taken for 
volume calculation. Results shown are the mean of 8 spheroids and error bars represent 
standard deviation. Spheroids were obtained from 10×103 cells. 
 
Spheroids exposed to the FeNS-CDDP also displayed a similar behaviour but with 
slower recovery rates in all cases. Most importantly, in the cases where thermotherapy and 
chemotherapy were applied concomitantly the final volume of the spheroids was 
significantly smaller than the one of the untreated conditions. These differences are better 
illustrated in Figure 6.11, where the percent increase in spheroid volume 24 days after 
treatment is plotted. If a Student’s t-test is applied to analyse the difference in the volume 
of untreated and treated spheroids, significant differences are seen for those subjected to 
simultaneous heat and drug therapy (two-tailed, paired test). At the most extreme 
situations, where the measured temperature was of 48 oC, an actual regression in spheroid 
volume is observed. These results confirm the combined effect of hyperthermia with 
cisplatin released directly from the nanomagnets. 
  
 
Figure 6.11. Increase in spheroid volume 24 days after thermotherapy. Results shown 
are the mean of 8 spheroids and error bars represent standard deviation. Asterisk (*) denotes 
significant differences in respect to untreated cells (p < 0.05). 
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Magnetic nanoparticles based on core-shell structures are promising candidates as 
heating agents for magnetic fluid hyperthermia. Here, two different nanoparticles based 
on a graphite shell encapsulating an iron core were studied in terms of their feasibility for 
this application and the potential functionalisation schemes that could be applied towards 
the development of a multifunctional structure. 
Of the two materials investigated (FeNS and FeNW), the FeNW have a very low heat 
dissipation when exposed to an alternating magnetic field, a consequence of the low 
relative amount of iron and thus, it was deemed not suitable for MFH. The FeNS, on the 
other hand, have a better potential for MFH where the material presents a high amount of 
iron, a stable graphitic shell and acceptable heat dissipation under an alternating magnetic 
field. Carboxylic functionalities can be generated on the graphitic shell by chemical 
treatments with dilute nitric acid. A trade-off is observed between the amount of 
functionalities obtained on its surface and the loss of iron by acid dissolution. Still, 
optimal conditions were found where the carboxylic functionalities are obtained alongside 
with a good preservation of magnetic properties. Moreover, increased heat dissipation is 
found in the functionalised material, even with the loss of iron. This behaviour is 
hypothesised to originate from a change in particle size distribution after the acidic 
treatments. Thus, in practical terms, such a functionalisation scheme improves the 
suitability of the nanoparticles for MFH with respect to the heat dissipation.  
The major goal of having carboxylic functionalities is the potential to covalently attach 
other molecules to the carbon shell. The feasibility of such approach was demonstrated 
via diimide-activated amidation where methylamine and a fluorescent probe were 
conjugated to the nanoparticles. It can thus be inferred that this method would also be 
suitable for the functionalisation with other molecules containing free amine groups such 
as proteins, which opens up a wide range of possibilities for functionalisation. As the 
uptake of the nanoparticles was shown in vitro, molecules conjugated to their surface can 
be delivered directly to the intracellular space. 
In addition to the covalent attachment of methylamine and a fluorescent dye, the 
carboxylic functionalities are also feasible as a bridge for the complexation with the drug 
cisplatin. It has been shown that the drug is still active when released from the 
7 
 nanoparticles in in vitro conditions, and that the amount of drug loaded can be tailored 
according to the amount of free carboxylic groups on the nanoparticle surface. The 
possibility to augment thermotherapy treatments was shown in vitro by using multicellular 
tumour spheroids, with their growth being effectively suppressed after the concomitant 
application of thermotherapy and chemotherapy. With this procedure, the nanoparticles 
become not only a heating agent, but also a drug carrier. As cisplatin is applied for a wide 
range of cancers, such a multifunctional nanoparticle could have an extensive application 
in oncology.  
When their effective use in clinical practice is considered, certain limitations must be 
taken into account. The most significant one is perhaps the amount of heat dissipated 
under an alternating magnetic field. The amount of heat obtained from the FeNS is still 
low in comparison with commercially available iron oxides, which means that 
improvements are necessary in this aspect. The FeNS used here have a broad size 
distribution, and a rather large average diameter (25 nm). As particle size distribution plays 
a very important role in the dissipation of heat by relaxation losses, one can expect to 
achieve better heating by using solutions containing particles with different sizes and with 
a narrower size distribution. As progresses are still being made in the development of 
these structures, it can be expected that a better control of particle size will be soon 
obtained in their production, allowing an optimisation of the characteristics which 
influence heat dissipation. 
Two other important aspects to be considered are colloidal stability in aqueous solutions 
and the biocompatibility. As with heating power, these two properties are also likely to 
vary with particle size distribution. In this work, methylcellulose was added as an additive 
to aid the suspensions of the particles which tended to sediment. Smaller nanoparticles, 
on the other hand, would likely be more stable in solution. Biocompatibility should also 
be studied in more detail when their medical applications are considered. The viability 
studies conducted in this work are useful to give a general impression on their cytotoxicity 
but further studies must be conducted in order to complement these findings, mainly in 
terms of oxidative stress that might be generated by nanoparticles.  
In summary, the surface modification methods developed in this work illustrate the 
range of possibilities that exist for adding new functionalities to nanoparticles containing a 
graphite coat. In order to take full advantage of the heating power that could be attained 
with metallic nanoparticles, the same methods should be explored with nanoparticles of 
optimal size distribution and larger specific absorption rates.  
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Thermal Enhancement Rate 
Ultraviolet - Visible 
Whole Body Hyperthermia 
Water-soluble Tetrazolium salt (viability reagent) 
X-Ray Photoelectron Spectroscopy 
X-Ray Diffraction 
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